1
|
Toyama H, Takahashi K, Shimizu T, Otaka I, Abe S, Kato S, Ando S, Sato T, Morii T, Fujita H, Waki H. Recurrent nocturnal hypoglycemic hemiplegia: a case report and review of the literature. Endocr J 2024; 71:409-416. [PMID: 38346770 DOI: 10.1507/endocrj.ej23-0324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/01/2024] Open
Abstract
A 67-year-old man with type 1 diabetes, Cronkhite-Canada syndrome, and membranous nephropathy who received insulin therapy was admitted to our hospital with right hemiplegia and dysarthria. Brain magnetic resonance imaging revealed a lesion with a high diffusion-weighted imaging signal and low apparent diffusion coefficient signal in the posterior limb of the left internal capsule. He was hypoglycemic with a blood glucose level of 56 mg/dL (3.1 mmol/L). Following glucose administration, the patient's symptoms resolved within several hours. The patient experienced similar transient hypoglycemic hemiplegia at midnight, three times within 10 days. In a literature review of 170 cases of hypoglycemic hemiplegia, 26 cases of recurrent hemiplegia were investigated. Recurrent hypoglycemic hemiplegia occurs more frequently on the right side than on the left side, and most recurrences occur within approximately a week, almost exclusively at midnight and in the early morning. We speculate that hypoglycemia-associated autonomic failure may be involved in the nocturnal recurrence of episodes. In our patient, depleted endogenous insulin secretion and lipodystrophy at the injection site, may have acted as additional factors, leading to severe hypoglycemia despite the absence of apparent autonomic neuropathy. Clinically, it is important to recognize hypoglycemia as a cause of hemiplegia to avoid unnecessary intervention and to maintain an appropriate blood glucose level at midnight and early in the morning to prevent recurrent hypoglycemic hemiplegia.
Collapse
Affiliation(s)
- Hanako Toyama
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Kazuyuki Takahashi
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Tatsunori Shimizu
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
- Advanced Research Center for Geriatric and Gerontology, Akita University, Akita 010-8543, Japan
| | - Izumi Otaka
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Sakiko Abe
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Shunsuke Kato
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
- Center for Medical Education and Training, Akita University Hospital, Akita 010-8543, Japan
| | - Sayaka Ando
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Takehiro Sato
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Tsukasa Morii
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Hiroki Fujita
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| | - Hironori Waki
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
| |
Collapse
|
2
|
Hiraga H, Machida R, Kawai A, Matsumoto Y, Yonemoto T, Nishida Y, Nagano A, Ae K, Yoshida S, Asanuma K, Toguchida J, Huruta D, Nakayama R, Akisue T, Hiruma T, Morii T, Tanaka K, Kataoka T, Fukuda H, Ozaki T. 1482O A phase III study comparing methotrexate (M), adriamycin (A) and cisplatin (P) with MAP + ifosfamide (MAP + IF) for the treatment of osteosarcoma: JCOG0905. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
3
|
Takahashi Y, Shimizu T, Kato S, Nara M, Suganuma Y, Sato T, Morii T, Yamada Y, Fujita H. Reduction of Superoxide Dismutase 1 Delays Regeneration of Cardiotoxin-Injured Skeletal Muscle in KK/Ta- Ins2Akita Mice with Progressive Diabetic Nephropathy. Int J Mol Sci 2021; 22:5491. [PMID: 34071003 PMCID: PMC8197123 DOI: 10.3390/ijms22115491] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 05/19/2021] [Accepted: 05/21/2021] [Indexed: 12/24/2022] Open
Abstract
Superoxide dismutase (SOD) is a major antioxidant enzyme for superoxide removal, and cytoplasmic SOD (SOD1) is expressed as a predominant isoform in all cells. We previously reported that renal SOD1 deficiency accelerates the progression of diabetic nephropathy (DN) via increasing renal oxidative stress. To evaluate whether the degree of SOD1 expression determines regeneration capacity and sarcopenic phenotypes of skeletal muscles under incipient and advanced DN conditions, we investigated the alterations of SOD1 expression, oxidative stress marker, inflammation, fibrosis, and regeneration capacity in cardiotoxin (CTX)-injured tibialis anterior (TA) muscles of two Akita diabetic mouse models with different susceptibility to DN, DN-resistant C57BL/6-Ins2Akita and DN-prone KK/Ta-Ins2Akita mice. Here, we report that KK/Ta-Ins2Akita mice, but not C57BL/6-Ins2Akita mice, exhibit delayed muscle regeneration after CTX injection, as demonstrated by the finding indicating significantly smaller average cross-sectional areas of regenerating TA muscle myofibers relative to KK/Ta-wild-type mice. Furthermore, we observed markedly reduced SOD1 expression in CTX-injected TA muscles of KK/Ta-Ins2Akita mice, but not C57BL/6-Ins2Akita mice, along with increased inflammatory cell infiltration, prominent fibrosis and superoxide overproduction. Our study provides the first evidence that SOD1 reduction and the following superoxide overproduction delay skeletal muscle regeneration through induction of overt inflammation and fibrosis in a mouse model of progressive DN.
Collapse
MESH Headings
- Animals
- Cardiotoxins/toxicity
- Collagen Type I/biosynthesis
- Collagen Type I/genetics
- Collagen Type I, alpha 1 Chain
- Diabetes Mellitus, Experimental/complications
- Diabetes Mellitus, Experimental/genetics
- Diabetic Nephropathies/complications
- Diabetic Nephropathies/enzymology
- Diabetic Nephropathies/genetics
- Diabetic Nephropathies/pathology
- Disease Progression
- Enzyme Induction/drug effects
- Fibrosis
- Gene Expression Regulation, Enzymologic
- Genetic Predisposition to Disease
- Glomerular Mesangium/pathology
- Inflammation
- Insulin/deficiency
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Mutant Strains
- Muscle, Skeletal/drug effects
- Muscle, Skeletal/enzymology
- Muscle, Skeletal/pathology
- Muscle, Skeletal/physiology
- Nerve Regeneration/drug effects
- Oxidative Stress/drug effects
- Sarcopenia/etiology
- Superoxide Dismutase-1/biosynthesis
- Superoxide Dismutase-1/drug effects
- Superoxide Dismutase-1/genetics
- Superoxide Dismutase-1/physiology
- Superoxides/metabolism
Collapse
Affiliation(s)
- Yuya Takahashi
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| | - Tatsunori Shimizu
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| | - Shunsuke Kato
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| | - Mitsuhiko Nara
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| | - Yumi Suganuma
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| | - Takehiro Sato
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| | - Tsukasa Morii
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| | - Yuichiro Yamada
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
- Kansai Electric Power Medical Research Institute, 2-1-7 Fukushima-ku, Osaka 553-0003, Japan
| | - Hiroki Fujita
- Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan; (Y.T.); (T.S.); (S.K.); (M.N.); (Y.S.); (T.S.); (T.M.); (Y.Y.)
| |
Collapse
|
4
|
Otomo H, Nara M, Kato S, Shimizu T, Suganuma Y, Sato T, Morii T, Yamada Y, Fujita H. Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy. Metabolism 2020; 113:154405. [PMID: 33069809 DOI: 10.1016/j.metabol.2020.154405] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2020] [Revised: 10/04/2020] [Accepted: 10/12/2020] [Indexed: 12/16/2022]
Abstract
AIMS The crosstalk between sodium-glucose cotransporter 2 (SGLT2) inhibition and a membrane-associated endocytic receptor megalin function involved in renal proximal tubular protein overload in progressive diabetic nephropathy (DN) is uncertain. Here, we determined whether SGLT2 inhibition affects megalin endocytic function through suppressing its O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) and protects the diabetic kidney from protein overload. MATERIALS AND METHOD We treated 8-week-old male non-obese and hypoinsulinemic KK/Ta-Ins2Akita (KK/Ta-Akita) mice which develop progressive DN with an SGLT2 inhibitor ipragliflozin or insulin for 6 weeks, and investigated the endocytic function (proximal tubular protein reabsorption), renal expression and O-GlcNAcylation of megalin along with their effects on renal phenotypes including histology and biochemical markers. RESULTS The treatment with ipragliflozin, but not insulin, suppressed megalin O-GlcNAcylation and accelerated its internalization, resulting in reduction in proximal tubular reabsorption of the highly filtered plasma proteins such as albumin and neutrophil gelatinase-associated lipocalin. These alterations following the ipragliflozin treatment contributed to amelioration of proximal tubular protein overload, mitochondrial morphological abnormality, and renal oxidative stress and tubulointerstitial fibrosis. CONCLUSIONS The present study provides a novel crosstalk mechanism between SGLT2 inhibition and megalin underlying the potential renal benefits of SGLT2 inhibition in DN.
Collapse
Affiliation(s)
- Hitomi Otomo
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Mitsuhiko Nara
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Shunsuke Kato
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Tatsunori Shimizu
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Yumi Suganuma
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Takehiro Sato
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Tsukasa Morii
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Yuichiro Yamada
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Hiroki Fujita
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
| |
Collapse
|
5
|
Adachi I, Ahlburg P, Aihara H, Akopov N, Aloisio A, Anh Ky N, Asner DM, Atmacan H, Aushev T, Aushev V, Aziz T, Babu V, Baehr S, Bambade P, Banerjee S, Bansal V, Barrett M, Baudot J, Becker J, Behera PK, Bennett JV, Bernieri E, Bernlochner FU, Bertemes M, Bessner M, Bettarini S, Bianchi F, Biswas D, Bozek A, Bračko M, Branchini P, Briere RA, Browder TE, Budano A, Burmistrov L, Bussino S, Campajola M, Cao L, Casarosa G, Cecchi C, Červenkov D, Chang MC, Cheaib R, Chekelian V, Chen YQ, Chen YT, Cheon BG, Chilikin K, Cho K, Cho S, Choi SK, Choudhury S, Cinabro D, Corona L, Cremaldi LM, Cunliffe S, Czank T, Dattola F, De La Cruz-Burelo E, De Nardo G, De Nuccio M, De Pietro G, de Sangro R, Destefanis M, Dey S, De Yta-Hernandez A, Di Capua F, Doležal Z, Domínguez Jiménez I, Dong TV, Dort K, Dossett D, Dubey S, Duell S, Dujany G, Eidelman S, Eliachevitch M, Fast JE, Ferber T, Ferlewicz D, Finocchiaro G, Fiore S, Fodor A, Forti F, Fulsom BG, Ganiev E, Garcia-Hernandez M, Garg R, Gaur V, Gaz A, Gellrich A, Gemmler J, Geßler T, Giordano R, Giri A, Gobbo B, Godang R, Goldenzweig P, Golob B, Gomis P, Gradl W, Graziani E, Greenwald D, Guan Y, Hadjivasiliou C, Halder S, Hara T, Hartbrich O, Hayasaka K, Hayashii H, Hearty C, Hedges MT, Heredia de la Cruz I, Hernández Villanueva M, Hershenhorn A, Higuchi T, Hill EC, Hoek M, Hsu CL, Hu Y, Iijima T, Inami K, Inguglia G, Irakkathil Jabbar J, Ishikawa A, Itoh R, Iwasaki Y, Jacobs WW, Jaffe DE, Jang EJ, Jeon HB, Jia S, Jin Y, Joo C, Joo KK, Kahn J, Kakuno H, Kaliyar AB, Kandra J, Karyan G, Kato Y, Kawasaki T, Kim BH, Kim CH, Kim DY, Kim KH, Kim SH, Kim YK, Kim Y, Kimmel TD, Kindo H, Kleinwort C, Kodyš P, Koga T, Kohani S, Komarov I, Korpar S, Kovalchuk N, Kraetzschmar TMG, Križan P, Kroeger R, Krokovny P, Kuhr T, Kumar J, Kumar M, Kumar R, Kumara K, Kurz S, Kuzmin A, Kwon YJ, Lacaprara S, La Licata C, Lanceri L, Lange JS, Lautenbach K, Lee IS, Lee SC, Leitl P, Levit D, Li LK, Li YB, Libby J, Lieret K, Li Gioi L, Liptak Z, Liu QY, Liventsev D, Longo S, Luo T, Maeda Y, Maggiora M, Manoni E, Marcello S, Marinas C, Martini A, Masuda M, Matsuda T, Matsuoka K, Matvienko D, Meggendorfer F, Mei JC, Meier F, Merola M, Metzner F, Milesi M, Miller C, Miyabayashi K, Miyake H, Mizuk R, Azmi K, Mohanty GB, Moon T, Morii T, Moser HG, Mueller F, Müller FJ, Muller T, Muroyama G, Mussa R, Nakano E, Nakao M, Nayak M, Nazaryan G, Neverov D, Niebuhr C, Nisar NK, Nishida S, Nishimura K, Nishimura M, Oberhof B, Ogawa K, Onishchuk Y, Ono H, Onuki Y, Oskin P, Ozaki H, Pakhlov P, Pakhlova G, Paladino A, Panta A, Paoloni E, Park H, Paschen B, Passeri A, Pathak A, Paul S, Pedlar TK, Peruzzi I, Peschke R, Pestotnik R, Piccolo M, Piilonen LE, Popov V, Praz C, Prencipe E, Prim MT, Purohit MV, Rados P, Rasheed R, Reiter S, Remnev M, Resmi PK, Ripp-Baudot I, Ritter M, Rizzo G, Rizzuto LB, Robertson SH, Rodríguez Pérez D, Roney JM, Rosenfeld C, Rostomyan A, Rout N, Russo G, Sahoo D, Sakai Y, Sandilya S, Sangal A, Santelj L, Sartori P, Sato Y, Savinov V, Scavino B, Schueler J, Schwanda C, Seddon RM, Seino Y, Selce A, Senyo K, Sfienti C, Shen CP, Shiu JG, Shwartz B, Sibidanov A, Simon F, Sobie RJ, Soffer A, Sokolov A, Solovieva E, Spataro S, Spruck B, Starič M, Stefkova S, Stottler ZS, Stroili R, Strube J, Sumihama M, Sumiyoshi T, Summers DJ, Suzuki SY, Tabata M, Takizawa M, Tamponi U, Tanaka S, Tanida K, Taniguchi N, Taras P, Tenchini F, Torassa E, Trabelsi K, Tsuboyama T, Uchida M, Unger K, Unno Y, Uno S, Ushiroda Y, Vahsen SE, van Tonder R, Varner GS, Varvell KE, Vinokurova A, Vitale L, Vossen A, Wakai M, Wakeling HM, Wan Abdullah W, Wang CH, Wang MZ, Warburton A, Watanabe M, Webb J, Wehle S, Wessel C, Wiechczynski J, Windel H, Won E, Yabsley B, Yamada S, Yan W, Yang SB, Ye H, Yin JH, Yonenaga M, Yuan CZ, Yusa Y, Zani L, Zhang Z, Zhilich V, Zhou QD, Zhou XY, Zhukova VI. Search for an Invisibly Decaying Z^{'} Boson at Belle II in e^{+}e^{-}→μ^{+}μ^{-}(e^{±}μ^{∓}) Plus Missing Energy Final States. Phys Rev Lett 2020; 124:141801. [PMID: 32338980 DOI: 10.1103/physrevlett.124.141801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Accepted: 02/24/2020] [Indexed: 06/11/2023]
Abstract
Theories beyond the standard model often predict the existence of an additional neutral boson, the Z^{'}. Using data collected by the Belle II experiment during 2018 at the SuperKEKB collider, we perform the first searches for the invisible decay of a Z^{'} in the process e^{+}e^{-}→μ^{+}μ^{-}Z^{'} and of a lepton-flavor-violating Z^{'} in e^{+}e^{-}→e^{±}μ^{∓}Z^{'}. We do not find any excess of events and set 90% credibility level upper limits on the cross sections of these processes. We translate the former, in the framework of an L_{μ}-L_{τ} theory, into upper limits on the Z^{'} coupling constant at the level of 5×10^{-2}-1 for M_{Z^{'}}≤6 GeV/c^{2}.
Collapse
Affiliation(s)
- I Adachi
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | | | - H Aihara
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - N Akopov
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - A Aloisio
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - N Anh Ky
- Institute of Theoretical and Applied Research (ITAR), Duy Tan University, Hanoi 100000, Vietnam
- Institute of Physics, Hanoi
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973
| | - H Atmacan
- University of Cincinnati, Cincinnati, Ohio 45221
| | - T Aushev
- Moscow Institute of Physics and Technology, Moscow Region 141700
| | - V Aushev
- Taras Shevchenko National Univ. of Kiev, Kiev
| | - T Aziz
- Tata Institute of Fundamental Research, Mumbai 400005
| | - V Babu
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Baehr
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P Bambade
- Laboratoire de l'Accélérateur Linéaire, IN2P3/CNRS et Université Paris-Sud 11, Centre Scientifique d'Orsay, F-91898 Orsay Cedex
| | - Sw Banerjee
- University of Louisville, Louisville, Kentucky 40292
| | - V Bansal
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - M Barrett
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - J Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - J Becker
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - P K Behera
- Indian Institute of Technology Madras, Chennai 600036
| | - J V Bennett
- University of Mississippi, University, Mississippi 38677
| | | | | | - M Bertemes
- Institute of High Energy Physics, Vienna 1050, Austria
| | - M Bessner
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Bettarini
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - F Bianchi
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - D Biswas
- University of Louisville, Louisville, Kentucky 40292
| | - A Bozek
- H. Niewodniczanski Institute of Nuclear Physics, Krakow 31-342
| | - M Bračko
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | | | - R A Briere
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213
| | - T E Browder
- University of Hawaii, Honolulu, Hawaii 96822
| | - A Budano
- INFN Sezione di Roma Tre, I-00146 Roma
| | - L Burmistrov
- Laboratoire de l'Accélérateur Linéaire, IN2P3/CNRS et Université Paris-Sud 11, Centre Scientifique d'Orsay, F-91898 Orsay Cedex
| | - S Bussino
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Campajola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - L Cao
- University of Bonn, 53115 Bonn
| | - G Casarosa
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - C Cecchi
- INFN Sezione di Perugia, I-06123 Perugia
- Dipartimento di Fisica, Università di Perugia, I-06123 Perugia
| | - D Červenkov
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - M-C Chang
- Department of Physics, Fu Jen Catholic University, Taipei 24205
| | - R Cheaib
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - V Chekelian
- Max-Planck-Institut für Physik, 80805 München
| | - Y Q Chen
- University of Science and Technology of China, Hefei 230026
| | - Y-T Chen
- Department of Physics, National Taiwan University, Taipei 10617
| | - B G Cheon
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - K Chilikin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Cho
- Korea Institute of Science and Technology Information, Daejeon 34141
| | - S Cho
- Yonsei University, Seoul 03722
| | - S-K Choi
- Gyeongsang National University, Jinju 52828
| | - S Choudhury
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - D Cinabro
- Wayne State University, Detroit, Michigan 48202
| | - L Corona
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - L M Cremaldi
- University of Mississippi, University, Mississippi 38677
| | - S Cunliffe
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - T Czank
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - F Dattola
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - E De La Cruz-Burelo
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - G De Nardo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - M De Nuccio
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - G De Pietro
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - R de Sangro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - M Destefanis
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - S Dey
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978
| | - A De Yta-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - F Di Capua
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - Z Doležal
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | | | - T V Dong
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - K Dort
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - D Dossett
- School of Physics, University of Melbourne, Victoria 3010
| | - S Dubey
- University of Hawaii, Honolulu, Hawaii 96822
| | - S Duell
- University of Bonn, 53115 Bonn
| | - G Dujany
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - S Eidelman
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | | | - J E Fast
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - T Ferber
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - D Ferlewicz
- School of Physics, University of Melbourne, Victoria 3010
| | - G Finocchiaro
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - S Fiore
- INFN Sezione di Roma, I-00185 Roma
| | - A Fodor
- McGill University, Montréal, Québec, H3A 2T8
| | - F Forti
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - B G Fulsom
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - E Ganiev
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - M Garcia-Hernandez
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
| | - R Garg
- Panjab University, Chandigarh 160014
| | - V Gaur
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - A Gaz
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - A Gellrich
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - J Gemmler
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - T Geßler
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - R Giordano
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - A Giri
- Indian Institute of Technology Hyderabad, Telangana 502285
| | - B Gobbo
- INFN Sezione di Trieste, I-34127 Trieste
| | - R Godang
- University of South Alabama, Mobile, Alabama 36688
| | - P Goldenzweig
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - B Golob
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Gomis
- Instituto de Fisica Corpuscular, Paterna 46980
| | - W Gradl
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | | | - D Greenwald
- Department of Physics, Technische Universität München, 85748 Garching
| | - Y Guan
- University of Cincinnati, Cincinnati, Ohio 45221
| | - C Hadjivasiliou
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - S Halder
- Tata Institute of Fundamental Research, Mumbai 400005
| | - T Hara
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - O Hartbrich
- University of Hawaii, Honolulu, Hawaii 96822
| | | | | | - C Hearty
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - M T Hedges
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Heredia de la Cruz
- Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico City 07360
- Consejo Nacional de Ciencia y Tecnología, Mexico City 03940
| | | | - A Hershenhorn
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - T Higuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - E C Hill
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | - M Hoek
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - C-L Hsu
- School of Physics, University of Sydney, New South Wales 2006
| | - Y Hu
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - T Iijima
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - K Inami
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - G Inguglia
- Institute of High Energy Physics, Vienna 1050, Austria
| | - J Irakkathil Jabbar
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - A Ishikawa
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Itoh
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - Y Iwasaki
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408
| | - D E Jaffe
- Brookhaven National Laboratory, Upton, New York 11973
| | - E-J Jang
- Gyeongsang National University, Jinju 52828
| | - H B Jeon
- Kyungpook National University, Daegu 41566
| | - S Jia
- Beihang University, Beijing 100191
| | - Y Jin
- INFN Sezione di Trieste, I-34127 Trieste
| | - C Joo
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - K K Joo
- Chonnam National University, Gwangju 61186
| | - J Kahn
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - H Kakuno
- Tokyo Metropolitan University, Tokyo 192-0397
| | - A B Kaliyar
- Tata Institute of Fundamental Research, Mumbai 400005
| | - J Kandra
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - G Karyan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - Y Kato
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - T Kawasaki
- Kitasato University, Sagamihara 252-0373
| | - B H Kim
- Seoul National University, Seoul 08826
| | - C-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - D Y Kim
- Soongsil University, Seoul 06978
| | - K-H Kim
- Yonsei University, Seoul 03722
| | - S-H Kim
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - Y K Kim
- Yonsei University, Seoul 03722
| | - Y Kim
- Korea University, Seoul 02841
| | - T D Kimmel
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - H Kindo
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - C Kleinwort
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - P Kodyš
- Faculty of Mathematics and Physics, Charles University, 121 16 Prague
| | - T Koga
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Kohani
- University of Hawaii, Honolulu, Hawaii 96822
| | - I Komarov
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - S Korpar
- J. Stefan Institute, 1000 Ljubljana
- University of Maribor, 2000 Maribor
| | - N Kovalchuk
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - P Križan
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - R Kroeger
- University of Mississippi, University, Mississippi 38677
| | - P Krokovny
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - T Kuhr
- Ludwig Maximilians University, 80539 Munich
| | - J Kumar
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213
| | - M Kumar
- Malaviya National Institute of Technology Jaipur, Jaipur 302017
| | - R Kumar
- Punjab Agricultural University, Ludhiana 141004
| | - K Kumara
- Wayne State University, Detroit, Michigan 48202
| | - S Kurz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - A Kuzmin
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | | | | | - C La Licata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - L Lanceri
- INFN Sezione di Trieste, I-34127 Trieste
| | - J S Lange
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | | | - I-S Lee
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S C Lee
- Kyungpook National University, Daegu 41566
| | - P Leitl
- Max-Planck-Institut für Physik, 80805 München
| | - D Levit
- Department of Physics, Technische Universität München, 85748 Garching
| | - L K Li
- University of Cincinnati, Cincinnati, Ohio 45221
| | - Y B Li
- Peking University, Beijing 100871
| | - J Libby
- Indian Institute of Technology Madras, Chennai 600036
| | - K Lieret
- Ludwig Maximilians University, 80539 Munich
| | - L Li Gioi
- Max-Planck-Institut für Physik, 80805 München
| | - Z Liptak
- University of Hawaii, Honolulu, Hawaii 96822
| | - Q Y Liu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - D Liventsev
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - S Longo
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - T Luo
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - Y Maeda
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - M Maggiora
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - E Manoni
- INFN Sezione di Perugia, I-06123 Perugia
| | - S Marcello
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - C Marinas
- Instituto de Fisica Corpuscular, Paterna 46980
| | - A Martini
- INFN Sezione di Roma Tre, I-00146 Roma
- Dipartimento di Matematica e Fisica, Università di Roma Tre, I-00146 Roma
| | - M Masuda
- Earthquake Research Institute, University of Tokyo, Tokyo 113-0032
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - T Matsuda
- University of Miyazaki, Miyazaki 889-2192
| | - K Matsuoka
- Graduate School of Science, Nagoya University, Nagoya 464-8602
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya 464-8602
| | - D Matvienko
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Novosibirsk State University, Novosibirsk 630090
| | | | - J C Mei
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE) and Institute of Modern Physics, Fudan University, Shanghai 200443
| | - F Meier
- Duke University, Durham, North Carolina 27708
| | - M Merola
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - F Metzner
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M Milesi
- School of Physics, University of Melbourne, Victoria 3010
| | - C Miller
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | | | - H Miyake
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - R Mizuk
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - K Azmi
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - G B Mohanty
- Tata Institute of Fundamental Research, Mumbai 400005
| | - T Moon
- Seoul National University, Seoul 08826
| | - T Morii
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), University of Tokyo, Kashiwa 277-8583
| | - H-G Moser
- Max-Planck-Institut für Physik, 80805 München
| | - F Mueller
- Max-Planck-Institut für Physik, 80805 München
| | - F J Müller
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - Th Muller
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - G Muroyama
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - R Mussa
- INFN Sezione di Torino, I-10125 Torino
| | - E Nakano
- Osaka City University, Osaka 558-8585
| | - M Nakao
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Nayak
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978
| | - G Nazaryan
- Alikhanyan National Science Laboratory, Yerevan 0036
| | - D Neverov
- Graduate School of Science, Nagoya University, Nagoya 464-8602
| | - C Niebuhr
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N K Nisar
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - S Nishida
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Nishimura
- University of Hawaii, Honolulu, Hawaii 96822
| | - M Nishimura
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - B Oberhof
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - K Ogawa
- Niigata University, Niigata 950-2181
| | - Y Onishchuk
- Taras Shevchenko National Univ. of Kiev, Kiev
| | - H Ono
- Niigata University, Niigata 950-2181
| | - Y Onuki
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - P Oskin
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - H Ozaki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Pakhlov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Physical Engineering Institute, Moscow 115409
| | - G Pakhlova
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Institute of Physics and Technology, Moscow Region 141700
| | - A Paladino
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - A Panta
- University of Mississippi, University, Mississippi 38677
| | - E Paoloni
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - H Park
- Kyungpook National University, Daegu 41566
| | | | - A Passeri
- INFN Sezione di Roma Tre, I-00146 Roma
| | - A Pathak
- University of Louisville, Louisville, Kentucky 40292
| | - S Paul
- Department of Physics, Technische Universität München, 85748 Garching
| | | | - I Peruzzi
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - R Peschke
- University of Hawaii, Honolulu, Hawaii 96822
| | | | - M Piccolo
- INFN Laboratori Nazionali di Frascati, I-00044 Frascati
| | - L E Piilonen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - V Popov
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
- Moscow Institute of Physics and Technology, Moscow Region 141700
| | - C Praz
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | - M T Prim
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - M V Purohit
- Okinawa Institute of Science and Technology, Okinawa 904-0495
| | - P Rados
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - R Rasheed
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - S Reiter
- Justus-Liebig-Universität Gießen, 35392 Gießen
| | - M Remnev
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - P K Resmi
- Indian Institute of Technology Madras, Chennai 600036
| | - I Ripp-Baudot
- Université de Strasbourg, CNRS, IPHC, UMR 7178, 67037 Strasbourg
| | - M Ritter
- Ludwig Maximilians University, 80539 Munich
| | - G Rizzo
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | | | - S H Robertson
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- McGill University, Montréal, Québec, H3A 2T8
| | | | - J M Roney
- Institute of Particle Physics (Canada), Victoria, British Columbia V8W 2Y2
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - C Rosenfeld
- University of South Carolina, Columbia, South Carolina 29208
| | - A Rostomyan
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - N Rout
- Indian Institute of Technology Madras, Chennai 600036
| | - G Russo
- INFN Sezione di Napoli, I-80126 Napoli
- Dipartimento di Scienze Fisiche, Università di Napoli Federico II, I-80126 Napoli
| | - D Sahoo
- Tata Institute of Fundamental Research, Mumbai 400005
| | - Y Sakai
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - S Sandilya
- University of Cincinnati, Cincinnati, Ohio 45221
| | - A Sangal
- University of Cincinnati, Cincinnati, Ohio 45221
| | - L Santelj
- J. Stefan Institute, 1000 Ljubljana
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana
| | - P Sartori
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - Y Sato
- Department of Physics, Tohoku University, Sendai 980-8578
| | - V Savinov
- University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - B Scavino
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - J Schueler
- University of Hawaii, Honolulu, Hawaii 96822
| | - C Schwanda
- Institute of High Energy Physics, Vienna 1050, Austria
| | - R M Seddon
- McGill University, Montréal, Québec, H3A 2T8
| | - Y Seino
- Niigata University, Niigata 950-2181
| | - A Selce
- INFN Sezione di Perugia, I-06123 Perugia
| | - K Senyo
- Yamagata University, Yamagata 990-8560
| | - C Sfienti
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - C P Shen
- Beihang University, Beijing 100191
| | - J-G Shiu
- Department of Physics, National Taiwan University, Taipei 10617
| | - B Shwartz
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - A Sibidanov
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - F Simon
- Max-Planck-Institut für Physik, 80805 München
| | - R J Sobie
- University of Victoria, Victoria, British Columbia, V8W 3P6
| | - A Soffer
- Tel Aviv University, School of Physics and Astronomy, Tel Aviv, 69978
| | - A Sokolov
- Institute for High Energy Physics, Protvino 142281
| | - E Solovieva
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| | - S Spataro
- INFN Sezione di Torino, I-10125 Torino
- Dipartimento di Fisica, Università di Torino, I-10125 Torino
| | - B Spruck
- Johannes Gutenberg-Universität Mainz, Institut für Kernphysik, D-55099 Mainz
| | - M Starič
- J. Stefan Institute, 1000 Ljubljana
| | - S Stefkova
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - Z S Stottler
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061
| | - R Stroili
- INFN Sezione di Padova, I-35131 Padova
- Dipartimento di Fisica e Astronomia, Università di Padova, I-35131 Padova
| | - J Strube
- Pacific Northwest National Laboratory, Richland, Washington 99352
| | - M Sumihama
- Gifu University, Gifu 501-1193
- Research Center for Nuclear Physics, Osaka University, Osaka 567-0047
| | - T Sumiyoshi
- Tokyo Metropolitan University, Tokyo 192-0397
| | - D J Summers
- University of Mississippi, University, Mississippi 38677
| | - S Y Suzuki
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Tabata
- Chiba University, Chiba 263-8522
| | - M Takizawa
- J-PARC Branch, KEK Theory Center, High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Theoretical Research Division, Nishina Center, RIKEN, Saitama 351-0198
- Showa Pharmaceutical University, Tokyo 194-8543
| | - U Tamponi
- INFN Sezione di Torino, I-10125 Torino
| | - S Tanaka
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency, Naka 319-1195
| | - N Taniguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - P Taras
- Université de Montréal, Physique des Particules, Montréal, Québec, H3C 3J7
| | - F Tenchini
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - E Torassa
- INFN Sezione di Padova, I-35131 Padova
| | - K Trabelsi
- Laboratoire de l'Accélérateur Linéaire, IN2P3/CNRS et Université Paris-Sud 11, Centre Scientifique d'Orsay, F-91898 Orsay Cedex
| | - T Tsuboyama
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - M Uchida
- Tokyo Institute of Technology, Tokyo 152-8550
| | - K Unger
- Institut für Experimentelle Teilchenphysik, Karlsruher Institut für Technologie, 76131 Karlsruhe
| | - Y Unno
- Department of Physics and Institute of Natural Sciences, Hanyang University, Seoul 04763
| | - S Uno
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - Y Ushiroda
- The Graduate University for Advanced Studies (SOKENDAI), Hayama 240-0193
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
- Department of Physics, University of Tokyo, Tokyo 113-0033
| | - S E Vahsen
- University of Hawaii, Honolulu, Hawaii 96822
| | | | - G S Varner
- University of Hawaii, Honolulu, Hawaii 96822
| | - K E Varvell
- School of Physics, University of Sydney, New South Wales 2006
| | - A Vinokurova
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - L Vitale
- INFN Sezione di Trieste, I-34127 Trieste
- Dipartimento di Fisica, Università di Trieste, I-34127 Trieste
| | - A Vossen
- Duke University, Durham, North Carolina 27708
| | - M Wakai
- University of British Columbia, Vancouver, British Columbia, V6T 1Z1
| | | | - W Wan Abdullah
- National Centre for Particle Physics, University Malaya, 50603 Kuala Lumpur
| | - C H Wang
- National United University, Miao Li 36003
| | - M-Z Wang
- Department of Physics, National Taiwan University, Taipei 10617
| | - A Warburton
- McGill University, Montréal, Québec, H3A 2T8
| | | | - J Webb
- School of Physics, University of Melbourne, Victoria 3010
| | - S Wehle
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | | | | | - H Windel
- Max-Planck-Institut für Physik, 80805 München
| | - E Won
- Korea University, Seoul 02841
| | - B Yabsley
- School of Physics, University of Sydney, New South Wales 2006
| | - S Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - W Yan
- University of Science and Technology of China, Hefei 230026
| | | | - H Ye
- Deutsches Elektronen-Synchrotron, 22607 Hamburg
| | - J H Yin
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - M Yonenaga
- Tokyo Metropolitan University, Tokyo 192-0397
| | - C Z Yuan
- Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049
| | - Y Yusa
- Niigata University, Niigata 950-2181
| | - L Zani
- INFN Sezione di Pisa, I-56127 Pisa
- Dipartimento di Fisica, Università di Pisa, I-56127 Pisa
| | - Z Zhang
- University of Science and Technology of China, Hefei 230026
| | - V Zhilich
- Budker Institute of Nuclear Physics SB RAS, Novosibirsk 630090
- Novosibirsk State University, Novosibirsk 630090
| | - Q D Zhou
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801
| | - X Y Zhou
- Beihang University, Beijing 100191
| | - V I Zhukova
- P.N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991
| |
Collapse
|
6
|
Suganuma Y, Shimizu T, Sato T, Morii T, Fujita H, Harada Sassa M, Yamada Y. Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes. J Diabetes Investig 2020; 11:389-399. [PMID: 31301103 PMCID: PMC7078094 DOI: 10.1111/jdi.13115] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Revised: 05/08/2019] [Accepted: 07/07/2019] [Indexed: 12/25/2022] Open
Abstract
AIMS/INTRODUCTION Pharmacological levels of glucagon-like peptide-1 (GLP-1) can decelerate gastric emptying (GE) and reduce postprandial glucose levels. Most previous studies have used liquid meals to evaluate GE. We evaluated the effects of GLP-1 receptor agonists (GLP-1 RAs) on GE and postprandial glucose excursion in Japanese type 2 diabetes mellitus patients using a combination of solid and liquid meals. MATERIALS AND METHODS In this single-center, prospective, open-label study, nine healthy individuals and 17 patients with type 2 diabetes mellitus consumed a 460-kcal combination of a solid and liquid meal labeled with 13 C-acetic acid. GE was measured from t = 0 to 150 min in a continuous 13 C breath test. Eight participants with type 2 diabetes mellitus were administered GLP-1 RAs, and we examined the relationship between GE and blood glucose excursion. RESULTS There were no differences in the average GE coefficient (GEC) and lag time between the healthy and type 2 diabetes mellitus groups. However, the type 2 diabetes mellitus group showed larger GEC variations (P < 0.05). The coefficient of variation of R-R intervals was a significant predictor of GEC in type 2 diabetes mellitus patients (P < 0.01). The short-acting GLP-1 RA reduced the GEC at 1 month (P = 0.012), whereas the long-acting GLP-1 RA did not significantly change the GEC after treatment. A positive relationship was observed between postprandial glucose excursion from T0 min to T60 min and the GEC (r2 = 0.75; P < 0.01). CONCLUSIONS The reduction in GE rate by the administration of GLP-1 RAs can predict the improvement in postprandial glucose excursion in type 2 diabetes mellitus patients.
Collapse
Affiliation(s)
- Yumi Suganuma
- Department of Endocrinology, Diabetes and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Tatsunori Shimizu
- Department of Endocrinology, Diabetes and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Takehiro Sato
- Department of Endocrinology, Diabetes and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Tsukasa Morii
- Department of Endocrinology, Diabetes and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Hiroki Fujita
- Department of Endocrinology, Diabetes and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Mariko Harada Sassa
- Institute for Advancement of Clinical and Translational ScienceKyoto University HospitalKyotoJapan
| | - Yuichiro Yamada
- Department of Endocrinology, Diabetes and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| |
Collapse
|
7
|
Hoizumi M, Sato T, Shimizu T, Kato S, Tsukiyama K, Narita T, Fujita H, Morii T, Sassa MH, Seino Y, Yamada Y. Inhibition of GIP signaling extends lifespan without caloric restriction. Biochem Biophys Res Commun 2019; 513:974-982. [PMID: 31003779 DOI: 10.1016/j.bbrc.2019.04.036] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Accepted: 04/04/2019] [Indexed: 01/02/2023]
Abstract
AIMS/INTRODUCTION Caloric restriction (CR) promotes longevity and exerts anti-aging effects by increasing Sirtuin production and activation. Gastric inhibitory polypeptide (GIP), a gastrointestinal peptide hormone, exerts various effects on pancreatic β-cells and extra-pancreatic tissues. GIP promotes glucose-dependent augmentation of insulin secretion and uptake of nutrients into the adipose tissue. MATERIALS AND METHODS Gipr-/- and Gipr+/+ mice were used for lifespan analysis, behavior experiments and gene expression of adipose tissue and muscles. 3T3-L1 differentiated adipocytes were used for Sirt1 and Nampt expression followed by treatment with GIP and α-lipoic acid. RESULTS We observed that GIP receptor-knockout (Gipr-/-) mice fed normal diet showed an extended lifespan, increased exploratory and decreased anxiety-based behaviors, which are characteristic behavioral changes under CR. Moreover, Gipr-/- mice showed increased Sirt1 and Nampt expression in the adipose tissue. GIP suppressed α-lipoic acid-induced Sirt1 expression and activity in differentiated adipocytes. CONCLUSIONS Although maintenance of CR is difficult, food intake and muscle endurance of Gipr-/- mice were similar to those of wild-type mice. Inhibition of GIP signaling may be a novel strategy to extend the lifespan of diabetic patients.
Collapse
Affiliation(s)
- Manabu Hoizumi
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Takehiro Sato
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Tatsunori Shimizu
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Shunsuke Kato
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Katsushi Tsukiyama
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Takuma Narita
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Hiroki Fujita
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Tsukasa Morii
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | - Mariko Harada Sassa
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Japan
| | - Yutaka Seino
- Kansai Electric Power Medical Research Institute, Osaka, Japan
| | - Yuichiro Yamada
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan.
| |
Collapse
|
8
|
Fukuoka Y, Narita T, Fujita H, Morii T, Sato T, Sassa MH, Yamada Y. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J Diabetes Investig 2019; 10:322-330. [PMID: 30098231 PMCID: PMC6400206 DOI: 10.1111/jdi.12908] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 07/04/2018] [Accepted: 08/06/2018] [Indexed: 12/18/2022] Open
Abstract
AIMS/INTRODUCTION To investigate the prevalence of sarcopenia, its related factors and indicators of physical evaluation in elderly diabetes patients. MATERIALS AND METHODS This was a cross-sectional observation study. A total of 267 diabetes patients (159 men, 108 women) aged >65 years were recruited in the present study. Skeletal muscle mass index, grip strength and usual gait speed were measured to diagnose sarcopenia according to the Asian Working Group for Sarcopenia. Body composition was measured using bioelectrical impedance analysis. Body mass index (BMI) and body fat percentage were evaluated in quartiles to investigate the relationship with sarcopenia. A multiple logistic regression analysis examined sarcopenia-related factors. RESULTS The prevalence of sarcopenia in all participants was 18.7% and increased with age. Sarcopenia decreased as BMI increased (P < 0.01, Cochran-Armitage test). In contrast, the third quartile body fat percentage group showed the lowest prevalence of sarcopenia. A strong positive correlation was observed between body mass and skeletal muscle mass indices (R = 0.702-0.682). Multiple logistic regression analysis showed that sarcopenia was associated with lower BMI, non-use of metformin and lower bone mineral content in men (P < 0.05), and lower bone mineral content, lower serum levels of albumin and older age in women (P < 0.05). CONCLUSIONS The present study suggests that diabetes patients with a high body fat percentage in addition to low BMI might develop sarcopenia. It is suggested that physical management in elderly diabetes patients should be carried out based on the evaluation of BMI and body fat percentage to prevent sarcopenia.
Collapse
Affiliation(s)
- Yuki Fukuoka
- Division of Endocrinology, Metabolism and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Takuma Narita
- Division of Endocrinology, Metabolism and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Hiroki Fujita
- Division of Endocrinology, Metabolism and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Tsukasa Morii
- Division of Endocrinology, Metabolism and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Takehiro Sato
- Division of Endocrinology, Metabolism and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| | - Mariko Harada Sassa
- Institute for Advancement of Clinical and Translational ScienceKyoto University HospitalKyotoJapan
| | - Yuichiro Yamada
- Division of Endocrinology, Metabolism and Geriatric MedicineAkita University Graduate School of MedicineAkitaJapan
| |
Collapse
|
9
|
Kondo M, Tanabe K, Amo-Shiinoki K, Hatanaka M, Morii T, Takahashi H, Seino S, Yamada Y, Tanizawa Y. Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome. Diabetologia 2018; 61:2189-2201. [PMID: 30054673 DOI: 10.1007/s00125-018-4679-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Accepted: 06/01/2018] [Indexed: 12/21/2022]
Abstract
AIMS/HYPOTHESIS Loss of functional beta cells results in a gradual progression of insulin insufficiency in Wolfram syndrome caused by recessive WFS1 mutations. However, beta cell dysfunction in Wolfram syndrome has yet to be fully characterised, and there are also no specific treatment recommendations. In this study, we aimed to characterise beta cell secretory defects and to examine the potential effects of a glucagon-like peptide-1 (GLP-1) receptor agonist on diabetes in Wolfram syndrome. METHODS Insulin secretory function was assessed by the pancreatic perfusion method in mice used as a model of Wolfram syndrome. In addition, granule dynamics in living beta cells were examined using total internal reflection fluorescence microscopy. Acute and chronic effects of exendin-4 (Ex-4) on glucose tolerance and insulin secretion were examined in young Wfs1-/- mice without hyperglycaemia. Molecular events associated with Ex-4 treatment were investigated using pancreatic sections and isolated islets. In addition, we retrospectively observed a woman with Wolfram syndrome who had been treated with liraglutide for 24 weeks. RESULTS Treatment with liraglutide ameliorated our patient's glycaemic control and resulted in a 20% reduction of daily insulin dose along with an off-drug elevation of fasting C-peptide immunoreactivity. Glucose-stimulated first-phase insulin secretion and potassium-stimulated insulin secretion decreased by 53% and 59%, respectively, in perfused pancreases of 10-week-old Wfs1-/- mice compared with wild-type (WT) mice. The number of insulin granule fusion events in the first phase decreased by 41% in Wfs1-/- beta cells compared with WT beta cells. Perfusion with Ex-4 increased insulin release in the first and second phases by 3.9-fold and 5.6-fold, respectively, in Wfs1-/- mice compared with perfusion with saline as a control. The physiological relevance of the effects of Ex-4 was shown by the fact that a single administration potentiated glucose-stimulated insulin secretion and improved glucose tolerance in Wfs1-/- mice. Four weeks of administration of Ex-4 resulted in an off-drug amelioration of glucose excursions after glucose loading in Wfs1-/- mice, with insulin secretory dynamics that were indistinguishable from those in WT mice, despite the fact that there was no alteration in beta cell mass. In association with the functional improvements, Ex-4 treatment reversed the increases in phosphorylated eukaryotic initiation factor (EIF2α) and thioredoxin interacting protein (TXNIP), and the decrease in phosphorylated AMP-activated kinase (AMPK), in the beta cells of the Wfs1-/- mice. Furthermore, Ex-4 treatment modulated the transcription of oxidative and endoplasmic reticulum stress-related markers in isolated islets, implying that it was able to mitigate the cellular stresses resulting from Wfs1 deficiency. CONCLUSIONS/INTERPRETATION Our study provides deeper insights into the pathophysiology of beta cell dysfunction caused by WFS1 deficiency and implies that activation of the GLP-1 receptor signal may alleviate insulin insufficiency and aid glycaemic control in Wolfram syndrome.
Collapse
Affiliation(s)
- Manabu Kondo
- Division of Endocrinology, Metabolism, Hematological Sciences and Therapeutics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan
| | - Katsuya Tanabe
- Division of Endocrinology, Metabolism, Hematological Sciences and Therapeutics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan.
| | - Kikuko Amo-Shiinoki
- Division of Endocrinology, Metabolism, Hematological Sciences and Therapeutics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan
| | - Masayuki Hatanaka
- Division of Endocrinology, Metabolism, Hematological Sciences and Therapeutics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan
| | - Tsukasa Morii
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Harumi Takahashi
- Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Susumu Seino
- Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuichiro Yamada
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Yukio Tanizawa
- Division of Endocrinology, Metabolism, Hematological Sciences and Therapeutics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan.
| |
Collapse
|
10
|
Takashima S, Fujita H, Fujishima H, Shimizu T, Sato T, Morii T, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, Seino Y, Yamada Y. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int 2016; 90:783-96. [PMID: 27475229 DOI: 10.1016/j.kint.2016.06.012] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Revised: 05/31/2016] [Accepted: 06/02/2016] [Indexed: 12/20/2022]
Abstract
The role of stromal cell-derived factor-1 (SDF-1) in the pathogenesis of diabetic nephropathy and its modification by dipeptidyl peptidase-4 (DPP-4) inhibition are uncertain. Therefore, we studied this independent of glucagon-like peptide-1 receptor (GLP-1R) signaling using two Akita diabetic mouse models, the diabetic-resistant C57BL/6-Akita and diabetic-prone KK/Ta-Akita. Increased SDF-1 expression was found in glomerular podocytes and distal nephrons in the diabetic-prone mice, but not in kidneys from diabetic-resistant mice. The DPP-4 inhibitor linagliptin, but not the GLP-1R agonist liraglutide, further augmented renal SDF-1 expression in both Glp1r(+/+) and Glp1r(-/-) diabetic-prone mice. Along with upregulation of renal SDF-1 expression, the progression of albuminuria, glomerulosclerosis, periglomerular fibrosis, podocyte loss, and renal oxidative stress was suppressed in linagliptin-treated Glp1r(+/+) diabetic-prone mice. Linagliptin treatment increased urinary sodium excretion and attenuated the increase in glomerular filtration rate which reflects glomerular hypertension and hyperfiltration. In contrast, selective SDF-1 receptor blockade with AMD3100 reduced urinary sodium excretion and aggravated glomerular hypertension in the Glp1r(+/+) diabetic-prone mice. Thus, DPP-4 inhibition, independent of GLP-1R signaling, contributes to protection of the diabetic kidney through SDF-1-dependent antioxidative and antifibrotic effects and amelioration of adverse renal hemodynamics.
Collapse
Affiliation(s)
- Satoru Takashima
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Hiroki Fujita
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan.
| | - Hiromi Fujishima
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Tatsunori Shimizu
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Takehiro Sato
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Tsukasa Morii
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Katsushi Tsukiyama
- Division of Metabolism and Clinical Nutrition Science, Akita University Graduate School of Medicine, Akita, Japan
| | - Takuma Narita
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| | - Takamune Takahashi
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Daniel J Drucker
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada; The Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada
| | - Yutaka Seino
- Kansai Electric Power Medical Research Institute, Osaka, Japan
| | - Yuichiro Yamada
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan
| |
Collapse
|
11
|
Campbell JE, Ussher JR, Mulvihill EE, Kolic J, Baggio LL, Cao X, Liu Y, Lamont BJ, Morii T, Streutker CJ, Tamarina N, Philipson LH, Wrana JL, MacDonald PE, Drucker DJ. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat Med 2015; 22:84-90. [DOI: 10.1038/nm.3997] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 10/26/2015] [Indexed: 12/18/2022]
|
12
|
Himuro Y, Miyagawa F, Fukumoto T, Morii T, Hasegawa M, Kobayashi N, Asada H. Hypersensitivity to influenza vaccine in a case of Epstein-Barr virus-associated T-lymphoproliferative disorder. Br J Dermatol 2015; 172:1686-1688. [DOI: 10.1111/bjd.13713] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Y. Himuro
- Department of Dermatology; Nara Medical University School of Medicine; 840 Shijo-cho Kashihara Nara 634-8522 Japan
| | - F. Miyagawa
- Department of Dermatology; Nara Medical University School of Medicine; 840 Shijo-cho Kashihara Nara 634-8522 Japan
| | - T. Fukumoto
- Department of Dermatology; Nara Medical University School of Medicine; 840 Shijo-cho Kashihara Nara 634-8522 Japan
| | - T. Morii
- Department of Hematology; Nara Medical University School of Medicine; 840 Shijo-cho Kashihara Nara 634-8522 Japan
| | - M. Hasegawa
- Department of Radiation Oncology; Nara Medical University School of Medicine; 840 Shijo-cho Kashihara Nara 634-8522 Japan
| | - N. Kobayashi
- Department of Dermatology; Nara Medical University School of Medicine; 840 Shijo-cho Kashihara Nara 634-8522 Japan
| | - H. Asada
- Department of Dermatology; Nara Medical University School of Medicine; 840 Shijo-cho Kashihara Nara 634-8522 Japan
| |
Collapse
|
13
|
Ishikawa M, Kato M, Sasaki H, Morii T, Fujita H, Kakei M, Narita T, Yamada Y. Poorly-controlled acromegaly accompanied by subclinical adrenal Cushing's syndrome after surgery for multiple endocrine tumors. Intern Med 2015; 54:617-20. [PMID: 25786452 DOI: 10.2169/internalmedicine.54.2782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 48-year-old woman diagnosed with acromegaly 21 years earlier presented at our hospital with a left adrenal tumor. Her medical history included breast cancer, thyroid cancer and an incompletely resected growth hormone (GH)-producing pituitary adenoma. Endocrinological and radiological examinations revealed subclinical adrenal Cushing's syndrome. She subsequently underwent left adrenalectomy, followed by glucocorticoid replacement therapy. Her GH and insulin-like growth factor-1 levels were insufficiently controlled, and pegvisomant was administered in addition to octreotide acetate. Following adrenalectomy, a giant hepatic hemangioma and papillary thyroid carcinoma in the residual right lobe developed, indicating the high risk of tumor development in patients with acromegaly.
Collapse
Affiliation(s)
- Motoko Ishikawa
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Narita T, Goto T, Suganuma Y, Hosoba M, Morii T, Sato T, Fujita H, Miura T, Shimotomai T, Yamada Y, Kakei M. Efficacy and safety of patient-directed titration of once-daily pre-dinner premixed biphasic insulin aspart 70/30 injection in Japanese type 2 diabetic patients with oral antidiabetic drug failure: STEP-AKITA study. J Diabetes Investig 2014; 2:63-70. [PMID: 24843463 PMCID: PMC4008017 DOI: 10.1111/j.2040-1124.2010.00062.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Aims/Introduction: To clarify clinical characteristics related to optimal glycemic control achieved after adding once‐daily pre‐dinner biphasic insulin aspart 70/30 (BIAsp 30) in Japanese type 2 diabetic (T2D) patients with oral antidiabetic drug (OAD) failure. Materials and Methods: Under this regimen, we evaluated changes in HbA1c levels and daily self‐monitoring blood glucose (BG) profiles, as well as the incidences of hypoglycemia and retinopathy progression. The patients adjusted BIAsp 30 dosages themselves every 3–4 days according to a pre‐determined algorithm to achieve fasting BG levels of 101–120 mg/dL. HbA1c levels were expressed as Japan Diabetes Society values. Results: Of 29 enrolled patients, 22 (HbA1c levels, 8.5 ± 1.5% [mean ± SD]) and 20 patients completed the 16‐ and 24‐week follow‐up, respectively. At 16 weeks 68.2 and 45.5%, and at 24 weeks 80.0 and 35% of patients had achieved HbA1c levels of <7.0 and <6.5%, respectively. The patients who had achieved optimal glycemic control, including daytime postprandial BG profiles after treatment, had lower post‐breakfast BG excursions at baseline, shorter diabetes durations and younger age. No severe hypoglycemic episodes were recorded. Progression of retinopathy was observed in 3 of the 29 enrolled patients. Conclusions: Lower post‐breakfast BG excursions, shorter diabetes duration and younger age in Japanese T2D patients with OAD failure might warrant optimal glycemic control with safety after adding once‐daily pre‐dinner BIAsp 30 initiating regimen. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00062.x, 2010)
Collapse
Affiliation(s)
- Takuma Narita
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo
| | | | - Yumi Suganuma
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo ; Akita Red Cross Hospital, Saruta, Kamikitate
| | - Mihoko Hosoba
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo ; Akita City Hospital, Kawamoto
| | - Tsukasa Morii
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo
| | - Takehiro Sato
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo
| | - Hiroki Fujita
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo
| | - Takeshi Miura
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo ; Akita City Hospital, Kawamoto
| | - Takashi Shimotomai
- Yokote Municipal Hospital, Yokote ; Akita Kumiai General Hospital, Ijima, Akita
| | - Yuichiro Yamada
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo
| | - Masafumi Kakei
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo ; Department of Medicine, Saitama Medical Center, Jichi Medical University, Omiya, Saitama, Japan
| |
Collapse
|
15
|
Morito H, Ogawa K, Fukumoto T, Kobayashi N, Morii T, Kasai T, Nonomura A, Kishimoto T, Asada H. Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms. Clin Exp Dermatol 2014; 39:284-91. [DOI: 10.1111/ced.12246] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/07/2013] [Indexed: 11/27/2022]
Affiliation(s)
- H. Morito
- Department of Dermatology; Nara Medical University School of Medicine; Nara Japan
| | - K. Ogawa
- Department of Dermatology; Nara Medical University School of Medicine; Nara Japan
| | - T. Fukumoto
- Department of Dermatology; Nara Medical University School of Medicine; Nara Japan
| | - N. Kobayashi
- Department of Dermatology; Nara Medical University School of Medicine; Nara Japan
| | - T. Morii
- Second Department of Internal Medicine; Nara Medical University School of Medicine; Nara Japan
| | - T. Kasai
- Department of Diagnostic Pathology; Nara Medical University School of Medicine; Nara Japan
| | - A. Nonomura
- Department of Diagnostic Pathology; Nara Medical University School of Medicine; Nara Japan
| | - T. Kishimoto
- Department of Psychiatry; Nara Medical University School of Medicine; Nara Japan
| | - H. Asada
- Department of Dermatology; Nara Medical University School of Medicine; Nara Japan
| |
Collapse
|
16
|
Fujita H, Fujishima H, Takahashi K, Sato T, Shimizu T, Morii T, Shimizu T, Shirasawa T, Qi Z, Breyer MD, Harris RC, Yamada Y, Takahashi T. SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2(Akita) diabetic mice. Metabolism 2012; 61:1714-24. [PMID: 22632894 PMCID: PMC4360989 DOI: 10.1016/j.metabol.2012.05.005] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2011] [Accepted: 01/12/2012] [Indexed: 01/06/2023]
Abstract
Superoxide dismutase (SOD) is a major defender against excessive superoxide generated under hyperglycemia. We have recently reported that renal SOD1 (cytosolic CuZn-SOD) and SOD3 (extracellular CuZn-SOD) isoenzymes are remarkably down-regulated in KK/Ta-Ins2(Akita) diabetic mice, which exhibit progressive diabetic nephropathy (DN), but not in DN-resistant C57BL/6- Ins2(Akita) (C57BL/6-Akita) diabetic mice. To determine the role of SOD1 and SOD3 in DN, we generated C57BL/6-Akita diabetic mice with deficiency of SOD1 and/or SOD3 and investigated their renal phenotype at the age of 20 weeks. Increased glomerular superoxide levels were observed in SOD1(-/-)SOD3(+/+) and SOD1(-/-)SOD3(-/-) C57BL/6-Akita mice but not in SOD1(+/+)SOD3(-/-) C57BL/6-Akita mice. The SOD1(-/-)SOD3(+/+) and SOD1(-/-)SOD3(-/-) C57BL/6-Akita mice exhibited higher glomerular filtration rate, increased urinary albumin levels, and advanced mesangial expansion as compared with SOD1(+/+)SOD3(+/+) C57BL/6-Akita mice, yet the severity of DN did not differ between the SOD1(-/-)SOD3(+/+) and SOD1(-/-)SOD3(-/-) C57BL/6-Akita groups. Increased renal mRNA expression of transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF), reduced glomerular nitric oxide (NO), and increased renal prostaglandin E2 (PGE2) production were noted in the SOD1(-/-)SOD3(+/+) and SOD1(-/-)SOD3(-/-) C57BL/6-Akita mice. This finding indicates that such renal changes in fibrogenic cytokines, NO, and PGE2, possibly caused by superoxide excess, would contribute to the development of overt albuminuria by promoting mesangial expansion, endothelial dysfunction, and glomerular hyperfiltration. The present results demonstrate that deficiency of SOD1, but not SOD3, increases renal superoxide in the setting of diabetes and causes overt renal injury in nephropathy-resistant diabetic mice, and that SOD3 deficiency does not provide additive effects on the severity of DN in SOD1-deficient C57BL/6-Akita mice.
Collapse
Affiliation(s)
- Hiroki Fujita
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, S-3223 MCN, Nashville, TN 37232, USA
- Correspondence to: H. Fujita, Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita 010-8543, Japan. Tel.: +81 18 884 6769; fax: +81 18 884 6449. (H. Fujita)
| | - Hiromi Fujishima
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Keiko Takahashi
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, S-3223 MCN, Nashville, TN 37232, USA
| | - Takehiro Sato
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Tatsunori Shimizu
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Tsukasa Morii
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Takahiko Shimizu
- Division of Molecular Gerontology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan
| | - Takuji Shirasawa
- Division of Molecular Gerontology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan
- Department of Aging Control Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, 3-3-10-201 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Zhonghua Qi
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, S-3223 MCN, Nashville, TN 37232, USA
| | - Matthew D. Breyer
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, S-3223 MCN, Nashville, TN 37232, USA
| | - Raymond C. Harris
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, S-3223 MCN, Nashville, TN 37232, USA
| | - Yuichiro Yamada
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Takamune Takahashi
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, S-3223 MCN, Nashville, TN 37232, USA
- Correspondence to: T. Takahashi, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, S-3223, MCN, Nashville, TN 37232, USA. Tel.: +1 615 343 4312; fax: +1 615 343 7156. (T. Takahashi)
| |
Collapse
|
17
|
Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012; 14:283-7. [PMID: 22051162 DOI: 10.1111/j.1463-1326.2011.01526.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To compare the effects of miglitol [an alpha-glucosidase inhibitor (AGI) absorbed in the intestine] and voglibose (an AGI not absorbed) on plasma glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) levels, 26 and 24 Japanese type 2 diabetic patients were randomly assigned to receive miglitol or voglibose, respectively. After 12-week administration of both drugs, during 2-h meal tolerance test, plasma glucose, serum insulin and total GIP were significantly decreased and active GLP-1 was significantly increased. Miglitol group showed a significantly lower total GIP level than voglibose group. Miglitol, but not voglibose, significantly reduced body weight (BW). In all participants, the relative change in BW was positively correlated with that of insulin significantly and of GIP with a weak tendency, but not of GLP-1. In conclusion, both drugs can enhance postprandial GLP-1 responses and reduce GIP responses. The significant BW reduction by miglitol might be attributable to its strong GIP-reducing efficacy.
Collapse
Affiliation(s)
- T Narita
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Fujita H, Fujishima H, Morii T, Sakamoto T, Komatsu K, Hosoba M, Narita T, Takahashi K, Takahashi T, Yamada Y. Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice. Hypertens Res 2011; 35:213-20. [PMID: 22072110 PMCID: PMC3273720 DOI: 10.1038/hr.2011.176] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Renal superoxide excess, which is induced by an imbalance of the superoxide-producing enzyme NAD(P)H oxidase and the superoxide-scavenging enzyme superoxide dismutase (SOD) under hyperglycemia, increases oxidative stress and contributes to the development of diabetic nephropathy. In this study, we treated non-obese and hypoinsulinemic C57BL/6-Ins2Akita (C57BL/6-Akita) diabetic mice with telmisartan (5 mg kg−1 per day), an angiotensin II type 1 receptor blocker, or amlodipine (5 mg kg−1 per day), a calcium channel blocker, for 4 weeks and compared the effects of these two anti-hypertensive drugs on renal NAD(P)H oxidase, SOD and transcription factor Nrf2 (NF-E2-related factor 2), which is known to upregulate several antioxidant enzymes including SOD. Vehicle-treated C57BL/6-Akita mice exhibited higher renal NAD(P)H oxidase and lower renal SOD activity with increased levels of renal superoxide than the C57BL/6-wild-type non-diabetic mice. Interestingly, telmisartan treatment not only reduced NAD(P)H oxidase activity but also enhanced SOD activity in C57BL/6-Akita mouse kidneys, leading to a reduction of renal superoxide levels. Furthermore, telmisartan-treated C57BL/6-Akita mice increased the renal protein expression of SOD and Nrf2. In parallel with the reduction of renal superoxide levels, a reduction of urinary albumin levels and a normalization of elevated glomerular filtration rate were observed in telmisartan-treated C57BL/6-Akita mice. In contrast, treatment with amlodipine failed to modulate renal NAD(P)H oxidase, SOD and Nrf2. Finally, treatment of C57BL/6-Akita mice with apocynin, an NAD(P)H oxidase inhibitor, also increased the renal protein expression of SOD and Nrf2. Collectively, our data suggest that NAD(P)H oxidase negatively regulates renal SOD, possibly by downregulation of Nrf2, and that telmisartan could upregulate renal SOD by the suppression of NAD(P)H oxidase and subsequent upregulation of Nrf2, leading to the amelioration of renal oxidative stress and diabetic renal changes.
Collapse
Affiliation(s)
- Hiroki Fujita
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University Graduate School of Medicine, Akita, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Morii T, Yamada Y. [Incretin-related medicine (GLP-1 receptor agonists, DPP-IV inhibitors)]. Nihon Rinsho 2010; 68 Suppl 9:181-185. [PMID: 21661154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Affiliation(s)
- Tsukasa Morii
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine
| | | |
Collapse
|
20
|
Hirao K, Maruyama T, Ohno Y, Hirose H, Shimada A, Takei I, Murata M, Morii T, Eguchi T, Hayashi M, Saruta T, Itoh H. Association of increased reactive oxygen species production with abdominal obesity in type 2 diabetes. Obes Res Clin Pract 2010; 4:e83-e162. [DOI: 10.1016/j.orcp.2009.09.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2009] [Revised: 09/11/2009] [Accepted: 09/23/2009] [Indexed: 01/04/2023]
|
21
|
Hosoba M, Fujita H, Miura T, Morii T, Shimotomai T, Koshimura J, Yamada Y, Ito S, Narita T. Diurnal changes in urinary excretion of IgG, transferrin, and ceruloplasmin depend on diurnal changes in systemic blood pressure in normotensive, normoalbuminuric type 2 diabetic patients. Horm Metab Res 2009; 41:910-5. [PMID: 19670106 DOI: 10.1055/s-0029-1233458] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Previous studies of diabetic patients indicate that increased urinary excretion of certain plasma proteins (molecular radii <55 A), such as IgG, transferrin, and ceruloplasmin, precede the development of microalbuminuria. Moreover, increases in these urinary proteins predict future development of microalbuminuria. To clarify whether blood pressure changes influence urinary excretion of these proteins, we examined relationships between diurnal blood pressure changes measured by ambulatory blood pressure monitoring and urinary excretion of IgG, transferrin, ceruloplasmin, alpha2-macroglobulin (88 A) and albumin (36 A) measured separately during the day and night in 20 healthy controls and 26 normotensive, normoalbuminuric diabetic patients. Diurnal change in systolic blood pressure was not correlated to urinary excretion of either albumin or alpha2-macroglobulin in either diabetic patients or controls. However, statistically significant correlations between diurnal changes in systolic blood pressure and those of urinary excretion of IgG, transferrin and ceruloplasmin were found in diabetic patients but not in controls. The present findings suggest that urinary excretion of IgG, transferrin, and ceruloplasmin are more easily affected than albuminuria by systemic blood pressure changes in normoalbuminuric diabetic patients. This is supported by our previous finding that urinary excretion of IgG, transferrin and ceruloplasmin increased while albuminuria did not following enhanced glomerular filtration rate after acute protein loading, which causes increased glomerular capillary pressure due to afferent arterioles dilation, mimicking diabetic intra-renal hemodynamics. Taken together, these findings suggest that urinary excretion of IgG, transferrin, and ceruloplasmin may be more sensitive indicators of glomerular capillary pressure change than albuminuria in normoalbuminuric diabetic patients.
Collapse
Affiliation(s)
- M Hosoba
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University School of Medicine, 010-8543 Akita, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
PURPOSE To report the outcomes of continuous decompression using a cannulated ceramic pin for simple bone cysts (SBCs). METHODS Seven boys and 3 girls aged 7 to 16 (mean, 11) years with SBCs underwent curettage and continuous decompression using a cannulated ceramic pin. The pin was made of hydroxyapatite and tricalcium phosphate. The clinical course, radiological findings, and complications were retrospectively assessed. RESULTS The mean follow-up duration was 41 (range, 12-84) months. Five patients were evaluated as 'healed', 2 as 'healing with defect', one as 'persistent cyst', and 2 as 'recurrent cysts'. No peri-operative complications were encountered. One patient had a postoperative fracture at the pin insertion site. Seven patients had pain relief and good outcomes; 2 had a thin cortical rim and complained of occasional pain and their sports activities were restricted. CONCLUSION Decompression using a cannulated ceramic pin for SBCs is minimally invasive, highly osteoconductive, and does not require bone grafting or a second operation to remove the device.
Collapse
Affiliation(s)
- T Morii
- Department of Orthopaedic Surgery, Kyorin University, Tokyo, Japan.
| | | | | |
Collapse
|
23
|
Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, Morii T, Yamada Y. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009; 26:187-8. [PMID: 19236625 DOI: 10.1111/j.1464-5491.2008.02651.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
24
|
Nakano S, Hasegawa T, Fukuda M, Fujieda N, Tainaka K, Morii T. Selective recognition of a tetra-amino-acid motif containing phosphorylated tyrosine residue by ribonucleopeptide. ACTA ACUST UNITED AC 2008:199-200. [DOI: 10.1093/nass/nrn101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
25
|
Morii T, Yabe H, Morioka H, Anazawa U, Suzuki Y, Toyama Y. Clinical significance of additional wide resection for unplanned resection of high grade soft tissue sarcoma. Open Orthop J 2008; 2:126-9. [PMID: 19478893 PMCID: PMC2687126 DOI: 10.2174/1874325000802010126] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2008] [Revised: 06/04/2008] [Accepted: 06/29/2008] [Indexed: 11/22/2022] Open
Abstract
Purpose: Unplanned resection of musculoskeletal sarcoma involves tumor excision without any suspicion of malignancy or regard for the necessity of defining adequate margins. For orthopaedic oncologists, many opportunities arise for management of unplanned resections initially performed by non-specialist surgeons. The puropose of this study is to assess the clinical outcomes and the problems of the patients with unplanned resection of high-grade soft tissue sarcoma. Methods: 77 consecutive patients were retrospectively reviewed. Oncological outcomes together with validity and problems of additional treatments were analyzed. Results: Five-year local recurrence-free survival, metastasis-free survival, event-free survival and total survival were 71.55%, 73.2%, 57.5% and 85.9%, respectively. Among adjuvant therapy including additional wide resection, radiotherapy and systemic chemotherapy, only additional wide resection significantly improved oncological outcomes. Conclusion: Additional wide resection appears to be effective in the treatment of high-grade soft tissue sarcomas following primary resection with compromised margins of resection.
Collapse
Affiliation(s)
- T Morii
- Department of Orthopaedics Surgery, Keio University School of Medicine, 35 Shinanomachi Shinjuku, Tokyo 160-8582, Japan
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
PURPOSE To evaluate treatment outcomes in patients with giant cell tumours after curettage and allograft reconstruction and to identify the risk factors for poor oncological and functional outcome. METHODS 29 patients with giant cell tumours of bone who underwent curettage and allograft reconstruction were retrospectively reviewed. The adjuvants used were heat treatment by electrocautery and hot water. Types of allograft used, time to bone union, complications, functional outcomes, and risk factors for poor function were analysed. RESULTS The mean time to bone union was 2.8 (range, 1-5) months. In 7 patients the tumours recurred (6 within 2 years); the 5-year recurrence-free survival rate was 77%. Three recurrences were classified as grade III and 4 as grade II; recurrence and the Campanacci grade showed a trend towards association (p=0.06). Tumour in the distal femur was a risk factor for postoperative fracture (p=0.02). Functional outcomes were excellent in 20 patients, good in 6, fair in 2, and a failure in one. The risk factors for poor function were recurrence (p=0.002) and joint instability (p=0.008) but not the Campanacci grade (p=0.10) or postoperative fracture (p=0.76). Lung metastasis, infection, and non-union were not encountered. CONCLUSION Despite a relatively high recurrence rate (24%), 26 (90%) of the 29 patients had excellent/good functional outcomes. We recommend the use of adjuvants and allografts for the management of giant cell tumours.
Collapse
Affiliation(s)
- T Morii
- Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
27
|
Narita T, Hosoba M, Miura T, Sasaki H, Morii T, Fujita H, Kakei M, Ito S. Low dose of losartan decreased urinary excretions of IgG, transferrin, and ceruloplasmin without reducing albuminuria in normoalbuminuric type 2 diabetic patients. Horm Metab Res 2008; 40:292-5. [PMID: 18548390 DOI: 10.1055/s-2008-1058075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- T Narita
- Department of Endocrinology, Diabetes, and Geriatric Medicine, Akita University School of Medicine, Akita, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Fujita H, Koshimura J, Sato T, Miura T, Sasaki H, Morii T, Narita T, Kakei M, Ito S, Yamada Y. Effects of long-term pravastatin treatment on serum and urinary monocyte chemoattractant protein-1 levels and renal function in type 2 diabetic patients with normoalbuminuria. Ren Fail 2008; 29:791-6. [PMID: 17994445 DOI: 10.1080/08860220701543056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
To explore the renoprotective and anti-inflammatory effects of pravastatin, we analyzed the changes in renal function and urinary monocyte chemoattractant protein-1 (MCP-1) level as a renal tubulointerstitial inflammatory biomarker and serum MCP-1 level as a systemic inflammatory biomarker following the introduction of treatment with 10 mg/day of pravastatin in 10 hyperlipidemic type 2 diabetic patients with normoalbuminuria. Twelve months of the pravastatin treatment did not affect urinary levels of albumin, transferrin, N-acetylglucosaminidase, or MCP-1 in the hyperlipidemic diabetic patients, whereas the treatment significantly reduced serum levels of MCP-1 in the patients. The pravastatin treatment effectively lowered low-density lipoprotein cholesterol (LDL-C) levels in the hyperlipidemic diabetic patients to levels nearly to those in 11 non-hyperlipidemic type 2 diabetic patients with normoalbuminuria. Interestingly, serum MCP-1 levels were significantly lower in the hyperlipidemic patients treated with pravastatin than in the non-hyperlipidemic patients. No significant correlation was observed between serum LDL-C and MCP-1 levels in all the data in the hyperlipidemic patients before and after the pravastatin treatment and in the non-hyperlipidemic patients. These results collectively indicate that pravastatin may ameliorate systemic vascular inflammation rather than local renal inflammation in hyperlipidemic type 2 diabetic patients with normoalbuminuria, independent of its cholesterol-lowering effects.
Collapse
Affiliation(s)
- Hiroki Fujita
- Division of Endocrinology, Metabolism and Geriatric Medicine, Department of Internal Medicine, Akita University School of Medicine, Akita, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Miura M, Kakei M, Iwasawa S, Morii T, Miura T, Sasaki H, Satoh T, Fujita H, Narita T, Shirakawa H, Yamada Y, Suzuki T. [Assessment of compliance for oral medicines with MMSE, Mini-Mental State Examination, in hospitalized elderly patients]. YAKUGAKU ZASSHI 2008; 127:1731-8. [PMID: 17917431 DOI: 10.1248/yakushi.127.1731] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The minimental state examination (MMSE) is a widely used, standardized method to assess cognitive function including movement-related disorders with high reliability. We studied the relationship between MMSE scores and the ability to take oral medications correctly (ingestion compliance) in 70 elderly inpatients (mean age 71.3+/-7.0 years). Patients with abnormal glucose tolerance as determined by an HbA(1c) level of 5.8% or greater including diabetes showed a trend of lower MMSE scores compared with patients with normal glucose tolerance, and the scores were negatively correlated with HbA1c, age, and systolic blood pressure (P<0.05). Self-management in taking oral medications was very difficult in 4 patients whose MMSE scores were 21 points or less. Thus ingestion supervisions by nurses were required in these patients. Furthermore, 9 of 12 noncompliant patients had MMSE scores ranging from 22 to 26 points. We instructed these patients to take medications in a one-dose package as a useful tool to improve compliance. The MMSE score was 27 or higher in 44 of 54 compliant patients, and 10 patients had scores ranging from 21 to 26. The sensitivity and specificity for noncompliance at an MMSE score cut-off point of 26 were 75.0% and 81.5%, respectively. In conclusion, it is necessary to coordinate ingestion methods matched to each patient according to their abilities to comply with medication schedules. They should be preevaluated with the MMSE to improve ingestion compliance. The MMSE is a recommended test in hospitalized elderly patients for the assessment of the ability to take medications safely.
Collapse
Affiliation(s)
- Masatomo Miura
- Department of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita City 010-8543, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Ishikawa M, Narita T, Sato T, Sasaki H, Miura T, Morii T, Fujta H, Yamada Y, Kakei M. Successful remission using metyrapone in an elderly patient with Cushing disease accompanied by generalized edema. Geriatr Gerontol Int 2007. [DOI: 10.1111/j.1447-0594.2007.00417.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Ohno Y, Kanno Y, Maruyama T, Morii T, Eguchi T, Hirao K, Takenaka T, Suzuki H. Attenuated radial augmentation index is associated with successful long-term antihypertensive treatment. J Hum Hypertens 2007; 22:144-6. [PMID: 17728800 DOI: 10.1038/sj.jhh.1002278] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Pulse wave analysis was performed in apparently normal volunteers (n=164) and in essentially hypertensive patients without cardiovascular complications (n=171) using a newly developed non-invasive pulse wave measurement device (HEM-9010AI). Our results suggest that early wave reflections measured by radial augmentation index (AIr) are enhanced in volunteers with systolic blood pressure (SBP) >or= 160 mm Hg compared with the volunteers with their SBP<160 mmHg (98+/-18 vs 88+/-12, P<0.05). Furthermore, AIr is lower in hypertensive patients with long-term antihypertensive treatment than in those with short-term treatment (84+/-10 vs 89+/-13, P<0.01).
Collapse
|
32
|
Fujita H, Kakei M, Fujishima H, Morii T, Yamada Y, Qi Z, Breyer MD. Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice. Biochem Biophys Res Commun 2007; 363:37-43. [PMID: 17825788 PMCID: PMC2211567 DOI: 10.1016/j.bbrc.2007.08.090] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2007] [Accepted: 08/14/2007] [Indexed: 12/27/2022]
Abstract
Previous studies have shown that Prostaglandin E(2) (PGE(2)) inhibits glucose-stimulated insulin secretion. However, the role of cyclooxygenase (COX)-1 vs. COX-2 derived PGE(2) production in glucose-stimulated insulin secretion remains poorly understood. Here we investigated the expression of COX-1 and COX-2 in pancreatic islets and the effect of selective inhibition of COX-1 and COX-2 on glucose-stimulated insulin secretion using C57BL/6 (B6) mice. Although immunofluorescence histochemistry showed the constitutive expression of both COX-1 and COX-2 in B6 mouse pancreatic islets, insulin secretion and hyperglycemia after glucose loading were ameliorated in B6 mice treated with selective COX-2 inhibitor (SC58236) for 18 weeks. Interestingly, incubation with selective COX-2 inhibitor for 24h led to a reduction in PGE(2) production in pancreatic islets isolated from B6 mice. In addition, selective COX-2 inhibition enhanced insulin secretion from the isolated islets. These results collectively suggest that selective inhibition of COX-2 enhances glucose-stimulated insulin secretion through a reduction in PGE(2) production in pancreatic islets.
Collapse
Affiliation(s)
- Hiroki Fujita
- Division of Endocrinology, Metabolism and Geriatric Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
| | | | | | | | | | | | | |
Collapse
|
33
|
Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, Sasaki H, Narita T, Ito S, Kakei M. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 2006; 53:745-52. [PMID: 16966829 DOI: 10.1507/endocrj.k06-016] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Adiponectin is an adipose-derived protein which has anti-inflammatory and anti-atherogenic properties in addition to insulin-sensitizing effects. To date, the role of adiponectin in the pathogenesis of diabetic nephropathy remains unclear. The aim of the present study was to explore the relationship between adiponectin and renal tubular injury in diabetic nephropathy. We determined serum and urinary adiponectin levels in type 2 diabetic patients with normoalbuminuria (n = 19), microalbuminuria (n = 18), and overt diabetic nephropathy (n = 16), and then analyzed the correlations between serum and urinary adiponectin, urinary N-acetylglucosaminidase (NAG) as a clinical marker of renal tubular injury, urinary monocyte chemoattractant protein-1 (MCP-1) as an inflammatory marker in renal tubulointerstitium, and clinical markers of renal disease. Notably, serum and urinary adiponectin levels were significantly increased in patients with overt diabetic nephropathy compared to those with normoalbuminuria and microalbuminuria. In univariate linear regression analysis, serum adiponectin levels were positively correlated with serum creatinine (r = 0.648, P<0.0001), urinary albumin (r = 0.583, P<0.0001), urinary NAG (r = 0.406, P<0.01), urinary MCP-1 (r = 0.514, P<0.0001), and urinary adiponectin (r = 0.691, P<0.0001) levels in all diabetic patients. Urinary adiponectin levels were also positively correlated with serum creatinine (r = 0.729, P<0.0001), urinary albumin (r = 0.799, P<0.0001), urinary NAG (r = 0.701, P<0.0001), and urinary MCP-1 (r = 0.801, P<0.0001) levels in all diabetic patients. Multiple linear regression analysis showed that serum creatinine and urinary adiponectin levels were independently associated with serum adiponectin levels (r(2) = 0.522), and that serum creatinine, urinary NAG, urinary MCP-1, and serum adiponectin levels were independent determinants of urinary adiponectin levels (r(2) = 0.851). These results collectively indicate that renal insufficiency and tubular injury possibly play a contributory role in increases in serum and urinary adiponectin levels in overt diabetic nephropathy. We presume that an increase in circulating adiponectin in overt diabetic nephropathy might be a physiological response to mitigate renal tubular injury and to prevent the further progression of diabetic nephropathy through its anti-inflammatory and anti-atherogenic effects.
Collapse
Affiliation(s)
- Hiroki Fujita
- Division of Endocrinology, Metabolism, and Geriatric Medicine, Department of Internal Medicine, Akita University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Takahashi T, Morii T, Amano I, Tanaka H, Tojo T, Taniguchi S, Kimura H. Remarkable response of adult-onset ganglioneuroblastoma in the advanced stage to unrelated cord blood transplantation: Case report. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.11524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11524 Background: Adult-onset ganglioneuroblastoma (GNB) is a rare disease that carries the gravest prognosis. In this case report, we discuss a case of adult-onset GNB in the advanced stage which has responded favorably to unrelated cord blood transplantation (UCBT). Methods: The patient was a 22-year-old male. Posterior mediastinal tumor was excised and a diagnosis of GNB was made. The severity of GNB was classified as stage IV because bone metastasis affected the entire body. Three courses of combination chemotherapy using cisplatin (CDDP), cyclophosphamide (CY), vincristine sulfate (VCR) and pirarubicin hydrochloride-adriamycin (THP-ADR) turned out to be ineffective. Local radiation therapy to control the tumor metastasis to the right great wing of the sphenoid bone resulted in augmentation of the tumorous lesion. Then, bone marrow destructive pretreatment consisting of anticancer therapy [etoposide (VP-16) and thiotepa] and total body irradiation (TBI, 12Gy) was followed by UCBT. Cyclosporin and mycophenolate mofetil were administered to prevent graft versus host disease (GVHD). Results: The blood type compatible two-loci HLA mismatch transplant had 3.2x107 nucleated cells/kg. After the cord blood transplantation, the patient suffered complications such as acute GVHD (grade III), veno-occlusive disease (VOD) and viral hemorrhagic cystitis. Neuron-specific enolase (NSE), a GNB tumor marker, gradually decreased from 220 ng/ml to the normal level. The bone metastatic tumors were reduced in a stepwise manner. Fluorodeoxyglucose-positron-emission tomography (FDG-PET) scan demonstrated complete disappearance of abnormal accumulation. Three hundred days have passed since the unrelated cord blood transplantation. The patient is surviving and in the disease-free state. Conclusion: The remarkable response of adult-onset GNB in the advanced stage to UCBT has demonstrated the definite graft versus tumor (GVT) effect of UCBT on GNB. UCBT is regarded as a promising therapeutic intervention in solid tumors that are not associated with blood disorder. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Takahashi
- Nara Medical University, Kashihara City, Nara, Japan
| | - T. Morii
- Nara Medical University, Kashihara City, Nara, Japan
| | - I. Amano
- Nara Medical University, Kashihara City, Nara, Japan
| | - H. Tanaka
- Nara Medical University, Kashihara City, Nara, Japan
| | - T. Tojo
- Nara Medical University, Kashihara City, Nara, Japan
| | - S. Taniguchi
- Nara Medical University, Kashihara City, Nara, Japan
| | - H. Kimura
- Nara Medical University, Kashihara City, Nara, Japan
| |
Collapse
|
35
|
Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, Ito S. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 2005; 52:427-33. [PMID: 16127210 DOI: 10.1507/endocrj.52.427] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Decreased circulating levels of adiponectin, a novel adipose-derived adipocytokine, in obesity possibly contribute to the development of insulin resistance which is a major factor in the pathogenesis of type 2 diabetes. The present study was conducted to examine whether circulating and adipose tissue adiponectin levels are modulated by chronic treatment with metformin and intensive treatment with insulin in murine models of obesity and type 2 diabetes, db/db mice with a C57BL/KsJ genetic background. Nine-week-old male db/db mice were treated with metformin, insulin, and vehicle for 4 weeks. Expectedly, metformin treatment led to inhibition of weight gain and improvement of hyperinsulinemia. Insulin treatment lowered fasting blood glucose levels to normal values, although it sustained hyperinsulinemic state. However, after 4 weeks of treatment, serum adiponectin levels were not significantly elevated in either metformin-treated or insulin-treated db/db mouse group (14.2 +/- 0.7 and 16.7 +/- 1.0 microg/ml, respectively) compared to vehicle-treated group (14.9 +/- 0.6 microg/ml). Similarly, adipose tissue adiponectin levels determined by Western blot analysis were not increased in either metformin-treated or insulin-treated group relative to vehicle-treated group. Recent studies have shown that adiponectin possibly has the same physiological effects on lipid and glucose metabolism that metformin has. Therefore, an elevation in blood concentration of metformin following the treatment might lead to suppression in adiponectin synthesis in adipose tissue, independent of inhibition in weight gain and improvement in hyperinsulinemia by metformin treatment. The present results indicate that adiponectin is not involved in the mechanism by which metformin treatment enhances insulin sensitivity. Moreover, our results suggest that adiponectin synthesis in adipose tissue may be suppressed under hyperinsulinemic state sustained by insulin treatment, even though hyperglycemia is markedly reduced. We conclude that antidiabetic treatment with metformin and insulin does not affect circulating and adipose tissue adiponectin levels.
Collapse
Affiliation(s)
- Hiroki Fujita
- Division of Endocrinology, Metabolism and Geriatric Medicine, Department of Internal Medicine, Akita University School of Medicine, Akita
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, Shimotomai T, Koshimura J, Fujita H, Kakei M, Ito S. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 2004; 27:1176-81. [PMID: 15111541 DOI: 10.2337/diacare.27.5.1176] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Increased urinary excretions of several plasma proteins with different molecular radii <55 A and different isoelectric points (pI), such as IgG, ceruloplasmin, transferrin, and orosomucoid, have been independently reported to precede the development of microalbuminuria in diabetic patients. We examined whether increases in urinary excretions of these proteins would be in parallel in the same patient. RESEARCH DESIGN AND METHODS Urinary excretion rates of proteins mentioned above in timed overnight urine samples were evaluated in 61 normoalbuminuric type 2 diabetic patients (group D) aged 40-60 years and in 17 age-matched control subjects (group C). RESULTS The excretion rates of these proteins were significantly higher in group D than in group C. These exhibited a strong linear correlation with each other and had a weak correlation with the excretion rate of N-acethylglucosaminidase. The excretion rate of alpha2-macroglobulin with large molecular radii of 88 A was not different between groups C and D, nor did they have any correlations with the excretion rates of the other proteins. Creatinine clearance and blood pressure levels in group D were significantly higher than those in group C. CONCLUSIONS In normoalbuminuric diabetic patients, excretion rates of plasma proteins with molecular radii <55 A increased in parallel with each other. In view of our previous finding that urinary excretions of these plasma proteins selectively increased in parallel with enhanced glomerular filtration rate after acute protein loading, the present finding may be explained by renal hemodynamic changes, such as increased intraglomerular hydraulic pressure.
Collapse
Affiliation(s)
- Takuma Narita
- Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University School of Medicine, Akita, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
|
38
|
Sato S, Makino K, Morii T. DNA binding of a basic leucine-zipper protein with novel folding domain. Nucleic Acids Symp Ser 2003:13-4. [PMID: 12903245 DOI: 10.1093/nass/44.1.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
DNA-binding proteins frequently utilize short alpha-helices as their critical DNA recognition elements. In this research, we have employed the structure-based design to construct a small domain that could target the specific DNA sequences recognized by the yeast transcriptional activator GCN4. The new DNA binding motif recognizes specific DNA sequences as a dimer with high affinity and specificity under the physiological conditions.
Collapse
Affiliation(s)
- S Sato
- Institute of Advanced Energy, Kyoto University, Uji, Kyoto 611-0011, Japan
| | | | | |
Collapse
|
39
|
Furusawa H, Morii T, Okahata Y. In vitro selection by using mutated GCN4-bZIP peptides for analysis of peptide-DNA interactions. Nucleic Acids Symp Ser 2003:245-6. [PMID: 12903360 DOI: 10.1093/nass/44.1.245] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
In vitro selection has been used as a method to determine the optimal binding site for DNA-binding proteins. We report here in vitro selection of dsDNA sequences that bind to mutated-GCN4-bZIP peptides. The GCN4-bZIP peptide mutated from alanine to histidine on a position-14 that contacts with DNA bound to different sequence from a binding site of wild type peptide.
Collapse
Affiliation(s)
- H Furusawa
- Department of Biomolecular Engineering, Tokyo Institute of Technology, Nagatsuda, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
| | | | | |
Collapse
|
40
|
Yamada M, Suzuki T, Kanaori K, Tajima K, Morii T, Makino K. NO induced novel DNA lesions: formation mechanism. Nucleic Acids Symp Ser 2003:273-4. [PMID: 12903374 DOI: 10.1093/nass/44.1.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
2'-Deoxyguanosine was treated with NO/O2 mixture at pH 7.0-7.8, and as well as the known major products such as 2'-deoxyxanthosine and 2'-deoxyoxanosine, some unidentified products were detected by RP-HPLC. In the present study, one of them has been characterized as a novel lesion, N2-nitro-2'-deoxyguanosine by spectrometric and chromatographic analysis. The mechanism for the production is also discussed.
Collapse
Affiliation(s)
- M Yamada
- Institute of Advanced Energy, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Hagihara M, Morii T, Makino K. Recognition of small molecules by a ribonucleopeptide. Nucleic Acids Res Suppl 2003:7-8. [PMID: 12836237 DOI: 10.1093/nass/1.1.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
In this research, we have design an ATP binding domain that consists of an RNA subunit and a peptide subunit by means of structure-based design approach and in vitro selection method. The RNA subunit is designed to consist of two functional domains; an ATP binding domain with 20 randomized nucleotides and an adjacent stem region that serves as a binding site for the RNA-binding peptide. RNA-peptide receptors to ATP were isolated from a pool of different RNAs by selection with affinity column and enzymatic amplification. Effects of the RNA-binding peptide for the specific ATP binding to the selected RNA-peptide receptors are discussed.
Collapse
Affiliation(s)
- M Hagihara
- Institute of Advanced Energy, Kyoto University, Kyoto, Japan
| | | | | |
Collapse
|
42
|
Yamada M, Honjo H, Hasegawa T, Morimoto E, Suzuki T, Morii T, Makino K. A novel detection method for 2'-deoxyoxanosine. Nucleic Acids Res Suppl 2003:159-60. [PMID: 12836313 DOI: 10.1093/nass/1.1.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
2'-Deoxyoxanosine (dOxo) is a novel DNA lesion produced from 2'-deoxyguanosine by the treatment with nitrous acid and nitric oxide. However, there has been no direct evidence on the formation of dOxo in vivo so far. In order to detect dOxo in vivo, we have explored a sensitive detection method specific for dOxo by using a fluorescent labeling reagent and HPLC analysis. An efficient method to detect the dOxo formation in DNA is described.
Collapse
Affiliation(s)
- M Yamada
- Institute of Advanced Energy, Kyoto University, Gokasho, Uji 611-0011, Japan
| | | | | | | | | | | | | |
Collapse
|
43
|
Morii T, Fujita H, Narita T, Koshimura J, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M, Ito S. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases. Ren Fail 2003; 25:439-44. [PMID: 12803507 DOI: 10.1081/jdi-120021156] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that is produced mainly by tubular epithelial cells in kidney and contributes to renal interstitial inflammation and fibrosis. More recently, we have demonstrated that urinary MCP-1 excretion is increased in proportion to the degree of albuminuria (proteinuria) and positively correlated with urinary N-acetylglucosaminidase (NAG) levels in type 2 diabetic patients. Based on these findings, we have suggested that heavy proteinuria, itself, probably aggravates renal tubular damage and accelerates the disease progression in diabetic nephropathy by increasing the MCP-1 expression in renal tubuli. In the present study, to evaluate whether urinary MCP-1 excretion is increased in the proteinuric states not only in diabetic nephropathy but also in other renal diseases, we examined urinary MCP-1 levels in IgA nephropathy patients with macroalbuminuria (IgAN group; n = 6), and compared the results with the data obtained from type 2 diabetic patients with overt diabetic nephropathy (DN group; n = 23) and those without diabetic nephropathy (non-DN group; n = 27). Urinary MCP-1 excretion levels in non-DN, DN, IgAN groups were 157.2 (52.8-378.5), 346.1 (147.0-1276.7), and 274.4 (162.2-994.5) ng/g creatinine, median (range), respectively. Expectedly, urinary MCP-1 and NAG excretion levels in DN and IgAN groups were significantly elevated as compared with non-DN group. Therefore, we suggest that MCP-1 expression in renal tubuli is enhanced in proteinuric states,irrespective of the types of renal disease, and that increased MCP-1 expression probably contributes to renal tubular damage in proteinuric states.
Collapse
Affiliation(s)
- Tsukasa Morii
- Department of Geriatric Medicine, Akita University School of Medicine, Hondo, Akita, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M, Ito S. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 2003; 17:11-5. [PMID: 12505750 DOI: 10.1016/s1056-8727(02)00176-9] [Citation(s) in RCA: 137] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Monocyte chemoattractant protein-1 (MCP-1), is a chemokine that mediates renal interstitial inflammation, tubular atrophy, and interstitial fibrosis by recruiting monocytes/macrophages into renal tubulointerstitium. Recent studies have demonstrated that protein overload in renal tubular cells up-regulates MCP-1 gene and its protein expression. Therefore, we hypothesized that increased expression of MCP-1 in renal tubuli, probably triggered by an increase in the leakage of plasma protein from glomerular capillary to tubular fluid, may contribute to renal tubular damage and accelerate the progression of diabetic nephropathy. To test this hypothesis, we examined urinary excretion levels of MCP-1 and N-acetylglucosaminidase (NAG), a sensitive marker of renal tubular damage, in Japanese Type II diabetic patients with normoalbuminuria (n=29), microalbuminuria (n=25), and macroalbuminuria (n=18). The median urinary excretion level of MCP-1 in patients with macroalbuminuria (394.4 ng/g creatinine) was significantly elevated compared to the levels in patients with normoalbuminuria and microalbuminuria (159.6 and 193.9 ng/g creatinine, respectively). Furthermore, the urinary MCP-1 excretion level was positively correlated with urinary excretion levels of albumin (r=.816, P<.001) and NAG (r=.569, P<.001) in all subjects. These results suggest that MCP-1 is produced in renal tubular cells and released into urine in proportion to the degree of proteinuria (albuminuria), and that increased MCP-1 expression in renal tubuli contributes to renal tubular damage. Therefore, we conclude that heavy proteinuria itself may accelerate the progression of diabetic nephropathy by increasing the MCP-1 expression in renal tubuli.
Collapse
Affiliation(s)
- Tsukasa Morii
- Department of Geriatric Medicine, Akita University School of Medicine, 1-1-1 Hondo, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Fujita H, Fujishima H, Morii T, Koshimura J, Narita T, Kakei M, Ito S. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun 2002; 298:345-9. [PMID: 12413946 DOI: 10.1016/s0006-291x(02)02464-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Resistin, a novel adipose-derived protein, has been proposed to cause insulin-resistant states in obesity. To evaluate whether an insulin-sensitizing drug, metformin, regulates adipose tissue resistin expression, murine models of obesity and diabetes, db/db mice, were treated with metformin (metformin group), insulin (insulin group), and vehicle (control group) for 4 weeks, followed by analyzing resistin protein expression in their adipose tissues. Unexpectedly, resistin protein expression was increased by 66% in the metformin group relative to the control group, while it did not differ between the insulin and control groups. Hyperinsulinemia was improved in the metformin group, while the insulin group exhibited severe hyperinsulinemia, similar to the control group. Furthermore, in comparison between obese mice (db/db mice) and age-matched lean controls, resistin protein expression was reduced by 58% in the obese mice with severe hyperinsulinemia. These data collectively suggest that resistin expression may be suppressed by hyperinsulinemia and that metformin may upregulate resistin expression via the improvement of hyperinsulinemia in obesity.
Collapse
Affiliation(s)
- Hiroki Fujita
- Department of Geriatric Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
| | | | | | | | | | | | | |
Collapse
|
46
|
Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002; 16:1259-66. [PMID: 12094249 DOI: 10.1038/sj.leu.2402526] [Citation(s) in RCA: 131] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2001] [Accepted: 02/20/2002] [Indexed: 11/09/2022]
Abstract
In order to improve the disappointing prognosis of adult patients with acute lymphoblastic leukemia (ALL), we applied similar induction therapy as that used for acute myeloid leukemia (AML), ie frequent administration of doxorubicin (DOX). DOX 30 mg/m(2) was administered from days 1 to 3 and from days 8 to 10 together with vincristine, prednisolone, cyclophosphamide and L-asparaginase, followed by three courses of consolidation and four courses of intensification. From December 1993 to February 1997, 285 untreated adult patients with de novo ALL were entered. Of 263 evaluable patients (age 15 to 59; median 31), 205 (78%) obtained complete remission (CR). At a median follow-up period of 63 months, the predicted 6-year overall survival (OS) rate of all patients was 33%, and disease-free survival (DFS) rate of CR patients was 30%, respectively. By multivariate analysis, favorable prognostic factors for the achievement of CR were age <40 and WBC <50 000/microl; for longer OS were age <30 and WBC <30 000/microl; and for longer DFS of CR patients were FAB L1 and ALT <50 IU/l. Among 229 patients who had adequate cytogenetic data, 51 (22%) had Philadelphia (Ph) chromosome. Ph-negative chromosome was a common favorable prognostic factor for CR, longer OS and DFS. DFS was not different between early sequential intensification (n = 48) and intermittent intensification (n = 43) during the maintenance phase. Among CR patients under 40 years old, the 6-year survival was not different between the allocated related allo-BMT group (34 patients) and the allocated chemotherapy group (108 patients). However, among patients with Ph-positive ALL, the survival of patients who actually received allo-BMT was superior to that of patients who received chemotherapy (P = 0.046).
Collapse
Affiliation(s)
- J Takeuchi
- First Department of Internal Medicine, Nihon University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Fujita H, Narita T, Morii T, Shimotomai T, Yoshioka N, Kakei M, Ito S. Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance. Ren Fail 2002; 24:69-75. [PMID: 11921700 DOI: 10.1081/jdi-120002662] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
N-acetylglucosaminidase (NAG) is a lysosomal enzyme produced by renal proximal tubular cells and has been widely used as a marker, which indicates a degree of renal tubular damage. An increase in urinary NAG excretion is though to result from the renal tubular damage. The aim of this study was to evaluate whether even mild hyperglycemia causes an increase in urinary excretion of NAG, which is a renal tubular protein. We examined urinary NAG excretion in overnight urine in 22 Japanese men with impaired glucose tolerance (IGT) for more than two years (IGT group) and 41 healthy control subjects matched in age, gender, BMI and blood pressure (control group). Urinary NAG excretion levels of IGT group and control group were 2.89 (1.23-7.97) and 2.22 (0.60-4.93) U/g creatinine, median (range), respectively. The IGT group showed significantly higher urinary excretion of NAG compared to the control group (p < 0.01). Several studies have indicated that plasma proteins filtered through the glomerular capillary may have intrinsic renal toxicity. Recently, we have reported that urinary excretion of plasma proteins (ceruloplasmin, IgG4 and IgG) with molecular radii of approximately 45-55 A is increased in subjects with IGT compared to healthy control subjects with normal glucose tolerance. Considering the present result together with our recent finding, we suggest that increased urinary excretion of NAG in the mildly hyperglycemic subjects may be due to the adverse effects of the plasma proteins highly filtered through the glomerular capillary on tubular cells.
Collapse
Affiliation(s)
- Hiroki Fujita
- Department of Geriatric Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
| | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
We investigated the reaction of Guo with nitrous acid in the presence of NaCl. When 1 mM Guo was incubated with 100 mM NaNO(2) and 2M NaCl in sodium acetate buffer at pH 3.2 and 37 degrees C, 2-chloroinosine (2-Cl-Ino) was produced in addition to oxanosine (Oxo) and xanthosine (Xao). The yield of 2-Cl-Ino was 0.033 mM at an incubation time of 2 h. Under the same reaction conditions, GMP and dGuo gave rise to the corresponding 2-chloro derivatives with comparable yields. All the 2-chloro derivatives were fairly stable (t(12)>360 h) at physiological pH and temperature. To elucidate the reaction mechanism of the chlorination, the diazoate derivative of Guo, a reaction intermediate of the Guo-HNO(2) system, was employed as a starting compound. When the diazoate was incubated with 2M NaCl in a neutral solution, 2-Cl-Ino was produced in addition to Oxo and Xao. These results suggest that the 2-chloro derivatives can be produced from foodstuffs in the human stomach and may have potential importance as a carcinogen causing gastric cancer.
Collapse
Affiliation(s)
- T Suzuki
- Institute of Advanced Energy, Kyoto University, Gokasho, 611-0011, Uji, Japan
| | | | | | | | | |
Collapse
|
49
|
Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S, Yano T. In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res 2001; 21:4147-51. [PMID: 11911309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
Chemotherapy is essential in the treatment of small round cell sarcomas. However, as yet there is no progress concerning the efficacy of chemotherapy in the treatment of other types of soft tissue tumors (STS). The Histoculture Drug Response Assay (HDRA) is an in vitro chemosensitivity test that has a high correlation with clinical response, the usefulness of which has been reported in various kinds of solid tumors. However, there has never been a report on its use in STS until now. In this study, in order to investigate the variation in chemosensitivity in STS, fresh biopsy or surgical samples of STS were tested using the HDRA method. Drug sensitivity testing by HDRA showed that two drugs, ADM and THP, had a significantly higher inhibitory rate than CDDP, IFOS, or VP-16 in the thirty-three soft tissue sarcomas tested. Depending on the morphological type, spindle cell sarcomas were sensitive to THP, which showed significantly higher inhibition rates than CDDP, IFOS, or VP-16. Small round cell sarcomas were relatively sensitive to all of the drugs tested. However the drug sensitivity of pleomorphic cell sarcoma was low except for ADM and THP, while its sensitivity to THP was higher than about 70%. However, there are numerous other soft tissue sarcomas that do not belong to these categories; drug sensitivity testing in each of them and the devising of individualized treatment strategies seems necessary to improve the therapeutic outcome.
Collapse
Affiliation(s)
- H Morioka
- Department of Orthopaedic Surgery, School of Medicine, Keio University, Tokyo, Japan.
| | | | | | | | | | | | | |
Collapse
|
50
|
Yoneda K, Amano I, Tanaka H, Yagi H, Tsukaguchi N, Morii T, Narita N. [Effective use of camostat mesilate for chronic disseminated intravascular coagulation complicated by thoracoabdominal aortic aneurysm]. Rinsho Ketsueki 2001; 42:30-4. [PMID: 11235131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
A 73-year-old man who had been receiving treatment for hypertension and angina pectoris was admitted to hospital following a transient ischemic attack. He was diagnosed as having chronic disseminated intravascular coagulation (DIC) complicated by a thoracoabdominal aortic aneurysm, and was treated with heparin sodium and a protease inhibitor. Although the DIC was controlled, the patient had to remain hospitalized in order to receive the medication by continuous infusion. Therefore, the heparin sodium and protease inhibitor were replaced by camostat mesilate, a drug suitable for oral administration and widely used for treatment of chronic pancreatitis. The drug proved effective for the chronic DIC, thus allowing the patient to receive regular treatment on an outpatient basis, and improving his quality of life.
Collapse
Affiliation(s)
- K Yoneda
- Second Department of Internal Medicine, Nara Medical University
| | | | | | | | | | | | | |
Collapse
|